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 Norsk Sammendrag 
Prevalensen av astma er økende både på verdensbasis og i Norge, og det er anslått at 
over 8 % av den voksne norske befolkningen lider av denne sykdommen (1). Resultater fra 
den store Miljø- og barneastmastudien i Oslo, hvor nærmere 1000 barn i Oslo ble fulgt fra 
fødsel og frem til ti års alder, viste en prevalens av astma på 11.1 % (2). Det er rapporter at 
over 80 % av astmapasienter har nese- og bihule plager (3, 4). Allergisk rhinitt er en av mange 
risikofaktorer for utvikling av astma, og epidemiologiske studier har vist at rhinitt kan 
utvikles flere år før astmasymptomene manifesterer seg (5-10). Derfor bør pasienter med 
langvarig rhinitt undersøkes i forhold til om de har astma, og astmatikere bør undersøkes om 
de har rhinitt og nesepolypose. Det er også viktig å ha en kombinert strategi for undersøkelse 
av de øvre- og nedre luftveier slik at denne pasientgruppen får optimalisert medikamentell 
behandling av hele luftveissystemet og kirurgisk behandling av de øvre luftveiene når dette er 
nødvendig (4). 
I dette doktorgradsprosjektet ser vi på nese-bihule symptomer, nese-bihule relatert 
livskvalitet og objektive målinger av romforhold og luftstrøm i nesen hos astmatikere og en 
ikke astmatisk kontrollgruppe. Ut i fra mitt ståsted som øre-nese-hals lege var det viktig å 
dokumentere ovennevnte forhold hos astmatikere, og større deler av avhandlingen omfatter de 
øvre - enn de nedre luftveier hos astmatikere. 
 Begrepet «The unified airway» (11, 12) beskriver respirasjonssystemet, fra nese og 
munnhule til den minste alveole, som en enhetlig luftvei og er sentral i denne avhandlingen. 
Avhandlingen konkluderer med at astmatikere spesielt, og sannsynligvis også andre 
pasientgrupper med sykdomsprosesser i luftveiene generelt, bør møtes med en tankegang om 
en enhetlig luftvei. 
 
Artikkel 1: Nittien astmapasienter og 95 ikke astmatiske kontrollpasienter ble undersøkt med 
spørreskjema angående nese- og bilhulesymptomer ved hjelp av visuelle analoge skalaer 
(VAS), og nese-bihule relatert livskvalitet, Sino-nasal outcome test 20 (SNOT-20). Maksimal 
luftstrøms hastighet gjennom nesen ble målt med Peak Nasal Inspiratory Flow (PNIF). 
Studien viste at astmatikere med og uten allergi hadde økte symptomer fra nese og bihuler, 
redusert nese-bihule relater livskvalitet og redusert inspiratorisk luftstrøm gjennom nesen 
sammenlignet med kontrollgruppen.  
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 Artikkel 2: Åttisyv astmapasienter og 91 ikke astmatiske kontroller ble undersøkt med 
akustisk rhinometri (AR) (volum og tverrsnitts areal) i nesen. Studien viste at astmatikere har 
lavere minste tverrsnitts areal og volum i nesekaviteten sammenlignet med kontrollgruppen, 
og at det minste tverrsnitts areal er 2-3 cm inn i nesen hos begge gruppene. Det var ingen 
forskjell i minste tverrsnitts areal mellom allergiske og ikke-allergiske individer hverken i 
astma og kontrollgruppen. 
 
Artikkel 3: I denne studien så vi på hvilke faktorer som kan virke inn på PNIF målinger hos 
87 astmapasienter sammenlignet med 92 ikke astmatiske kontroller. Studien viste at PNIF 
påvirkes av astma, forsert ekspiratorisk volum i løpet av 1 sekund (% av forventet) (FEV1 (% 
predicted)), grad av nesetetthet målt subjektivt med VAS og objektivt med AR, alder og 
sykdomsstatus. Dette medfører at det må utøves ekstra oppmerksomhet når PNIF verdier hos 
pasienter med astma eller redusert FEV1 (% predicted) skal vurderes. Astmapasienter hadde 
19 ganger større sannsynlighet for å være i en høyere NO-VAS kategori sammenlignet med 
ikke astmatiske kontroller uavhengig av hvilken PNIF gruppe de tilhørte (lav, middels, høy 
nasal luftstrøm). 
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 1 Introduction  
 The concept of the Unified Airway model considers the entire respiratory system from 
the nose and paranasal sinuses, oropharynx, larynx, trachea, large and small airways as one 
integrated unit (12). The upper airway is a complicated structure comprising the nasal 
passages and the mouth placed in parallel, where the nose contains two parallel pathways for 
airflow. Unlike the lower airway, the nasal mucosa contains venous sinusoids that undergo 
periodic congestion and decongestion (the nasal cycle) which is essential in filtering, warming 
and humidifying the inspired air for the best of the lower airway. 
It has become increasingly clear that inflammation in the upper respiratory tract affects 
the lower respiratory tract and vice versa. More than 80 % of adult patients with allergic and 
non-allergic asthma have symptoms of rhinitis (3, 4, 13),  and the co-existence of asthma and 
allergic rhinitis is associated with more severe asthma symptoms, reduced asthma related 
quality of life (QoL), and greater challenges in acquiring control over the lower airway 
symptoms (14). Conversely, 20–50% of patients with rhinitis have asthma (15), and an 
increase in nonspecific bronchial responsiveness is seen in patients with allergic rhinitis 
without obvious asthma (16).  
 Asthma is a global health problem, with increasing prevalence in most countries, and 
an estimated 300 million sufferers worldwide (17). In Norway, the prevalence of asthma in 
adults is estimated to 8 % (1). The “Environment and Childhood Asthma (ECA) Study” in 
Oslo found a prevalence of current asthma of 11.1% (2). 
  The concept of the unified airway is based on evidence from epidemiological (5-10), 
pathophysiological (18-20) and treatment outcome studies (21, 22). However, there are few 
studies that have investigated the upper airway characteristics in asthmatics using subjective 
and objective tools (23, 24). As en ENT specialist, the purpose of this thesis has been to focus 
on the structural, functional and subjective characteristics of the noses in asthmatics by 
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 evaluating the association between their subjective sino-nasal complaints, sino-nasal quality 
of life and nasal airway patency compared with non-asthmatic controls. 
 
1.1 The Unified Airways in health 
1.1.1 Anatomy of the Unified Airway 
1.1.1.1 Upper airway  
External nose and nasal vestibule  
The external nose consists of 3 parts; the lobule, the cartilaginous pyramid and the 
bony pyramid. The lobule (lower 1/3) consists of the medial and lateral crus of the lobular 
cartilages and soft tissues. The cartilaginous pyramid (middle 1/3) consists of two upper 
lateral cartilages and septal cartilages. The bony pyramid (superior 1/3) consists of the nasal 
spine of the frontal bone, the frontal processes of the maxilla and two nasal bones (figure 1). 
 
 
 
Figure 1. Anatomy of the nose, frontal and lateral view. Illustration Marianne Husnes© 
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 The cartilages counteract collapse and provide rigidity for the nasal vestibule and alae regions 
during respiration. The nasal vestibule is the anterior segment of the nasal cavity, which is 
defined by the columella, the membranous septum and the inside of the alae cartilages, and 
these parts define the external nasal valve, figure 2.  
 
Figure 2. Anatomy of the nasal entrance. Illustration Marianne Husnes© 
 
 
Nasal valve and internal nose  
The internal nasal valve, also referred to as “the internal ostium” or “isthmus nasi”, is  
the relative stenosis forming the transition between the skin-lined nasal vestibule and the 
mucosa-lined nasal cavity (25).The anatomical boundaries include the septum, the upper 
lateral cartilages, the piriform aperture and the anterior end of the inferior turbinates and 
septal body (26, 27), figure 3. 
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Figure 3. The nasal valve region, sagittal view. Modified from Cole (28) and the thesis of Thomas Kjærgaard. 
Illustration Marianne Husnes© 
 
The nasal cavity dimensions rapidly increase beyond the nasal valve region. The nasal 
cavity is divided in two compartments by the nasal septum, which consists of a cartilaginous 
and a bony part, and it is lined by a respiratory mucosa. The lateral nasal wall consists of 3 to 
4 turbinates: the inferior, middle, superior, and in some individuals’ also supreme turbinates. 
The turbinates consist of a bony core coated with respiratory mucosa and a characteristic 
cavernous tissue embedded in the lamina propria. This cavernous tissue is mostly developed 
in the inferior turbinates and varies in size. Thus the inferior turbinates contribute 
significantly to regulation of nasal air flow (29, 30). The sinuses are paired organs which are 
divided into 4 compartments; maxillary sinuses, ethmoid sinuses, frontal sinuses and sphenoid 
sinuses, all lined with respiratory epithelium. Patency of the sinus ostia, and intact innate and 
adaptive immune systems are mandatory to obtain normal sinus function. 
 
Nasal mucosa 
The respiratory pseudostratified columnar epithelium lines the entire airway, including 
the tuba auditiva and middle ear. The sinonasal mucosa is comprised of ciliated columnar 
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 epithelial cells (80%), goblet cells that produce mucus (15%), and progenitor basal cells (5%) 
(31). The epithelium is covered by an airway surface liquid (ASL) about 10 µm deep. It is in 
two layers, the sol layer and the gel layer. The watery periciliary sol is surrounding the cilia. 
Over the sol layer is the gel layer which works as a mucous blanket that traps inhaled particles 
(32). The low viscosity of the periciliary sol allows the cilia to beat and propel the mucous 
blanket to the oropharynx, where it is swallowed or expectorated. In the normal “resting” 
nose, 20-40 ml of mucus are secreted each day from the nasal mucosa (33).  
Each epithelial cell has approximately 50 to 200 cilia (31). Ciliary ultra structure is 
characterized by axonema composed of microtubules with interconnecting dynein arms which 
enables a biphasic ciliary beat (34). During their active stroke the cilia contact the underside 
of the mucous gel, and propel the mucus and entrapped particles at ∼3 mm/min (35). In 
addition, the epithelial cells have hundreds of immotile microvilli which are hairlike 
projections of actin filaments, 1 to 2 μm in lengths covered by cell membrane. When 
increasing the total mucosal surface, the microvilli aid in sinonasal sensation, warming and 
humidifying the inspired air (36, 37).  
 
Arteries and nerves of the nasal cavity 
The arterial blood supply to the nasal cavity consists of the anterior and posterior 
ethmoid arteries, via the ophthalmic artery from the internal carotid artery, and the 
sphenopalatine artery, via the maxillary artery from the external carotid artery. The ethmoid 
arteries supply blood to the superior and frontal parts of the nose and septum, and the 
sphenopalatine artery supplies the posterior parts of the nose and septum. The anterior part of 
the nose is supplied from alar branches of the facial artery, and septal branches of the superior 
labial artery, via the facial artery. The arterial blood flow runs anteriorly against inspiration 
and may warm incoming air (38). 
17 
 The first cranial nerve, the olfactory tract, ends at the cribriform plate of the ethmoid 
bone. Olfactory nerves are found on the superior and middle turbinates and on the upper parts 
of the nasal septum. The trigeminal nerve (cranial nerve V) conducts sensory impulses like 
temperature, pain and touch from the nose (26). The autonomic innervation of the nasal cavity 
(Vidian nerve) regulates blood flow to the nasal mucosa (sympathetic system) and nasal 
secretions (parasympathetic system) (26). 
 
1.1.1.2 Middle airway 
The Waldeyer´s ring (39) is located at the opening of the respiratory and digestive 
tract and is continuously exposed to foreign pathogens and airborne antigens entering the 
body through the nose and mouth. It consists of the adenoids, the paired tubal tonsils, the 
lingual tonsils and the paired palatine tonsils. The Waldeyer's ring is most prominent during 
childhood, when the size of the oro-nasopharyngeal space is not yet fully developed, but 
decreases spontaneously with age. The larynx consists of the epiglottis, and the thyroid-, 
arytenoid-, cricoid- and accessory cartilages. 
In this thesis the Waldeyer´s ring and the larynx are defined as parts of the middle airway. 
 
1.1.1.3 Lower airway 
The trachea is a mucosa covered cartilaginous tube, extending from the lower part of 
the larynx at the level of the 6th cervical vertebrae to the upper border of the 5th thoracic 
vertebra where it divides at the carina into the 2 bronchi. The right main bronchus is wider, 
shorter and more vertical than the left. The right and left main bronchi divide into 3 and 2 
lobar bronchi, respectively. The lobar bronchi divide into tertiary bronchi which supply a 
bronchopulmonary segment. The pulmonary alveoli are the terminal ends of the respiratory 
tree, which outcrop from either alveolar sacs or alveolar ducts. The alveolar membrane is the 
18 
 gas-exchange surface. Carbon dioxide rich blood is pumped from the rest of the body into the 
alveolar blood vessels where carbon dioxide is released and oxygen is absorbed through 
diffusion. 
 
1.1.2 Physiology of the Unified Airway 
The two major functions of the nose are nasal breathing and olfaction, and the major 
function of the lower airway is transportation of air and gas exchange.  
 
1.1.2.1 Upper airway 
The nose is used for inhalation and exhalation of air, and olfaction, and an open nose 
is essential for human health and normal lung function. During inspiration the air is filtered, 
tempered, humidified and supplied with nitric oxide (NO) before entering the lower airways.  
The efficacy of the filter of the nose depends on the size of the inhaled particles. During 
normal breathing, only a few particles larger than 10 µm (pollen grains) enter the lower 
airways, while most particles smaller than 2 µm (mould spores) can easily bypass the nose 
without being trapped in the mucous blanket (40). Conditioning (heating and humidification) 
of the inspired air is important as cold and dry air are known to cause bronchoconstriction in 
sensitive asthmatic patients (41-43). By adjusting the mucosal blood flow, the nose can either 
warm and humidify or extract heat and water from the passing air (44).  
The effects of NO are explained later in the text. 
The pattern of airflow in the nasal airway is complex, and to be able to understand it, 
the basic principles of flow of fluids have to be understood. (The equations of the physical 
laws of fluid mechanics are given in the appendix). 
In laminar flow a fluid, i.e. a liquid or gas, proceeds through a tube in a predictable 
manner, as in a river where the water near the banks is almost still and whereas that in the 
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 center flows more rapidly. Further, Venturi tubes consist of constricted and dilated segments, 
and are used in industrial and scientific laboratories for measuring the flow of liquids. When 
gas flows through a Venturi tube and the flow at the two ends is constant, the Bernoulli’s 
principle states that the velocity of the flow within the tube varies. This principle implicates 
that velocity of flow in constricted areas is increased whereas it is decreased in the dilated 
areas, as in a river where the flow slows when it enlarges into a basin. The Bernoulli's 
principle also applies for  the nose, where the velocity of the airflow through constricted 
segments is increased as opposed to decreased through dilated segments (45). In a Venturi 
tube, the pressure is reduced in areas where the flow is fast, whereas the pressure is increased 
in areas where the flow is slow. Poiseuille’s law (46) is another physical law which is 
important for airflow. It states that the flow is directly proportional to the difference in 
pressure times the radius raised to the 4th power. Consequently, minimal increases in the size 
of the tube or nasal airway cause exponential increases in airflow. Flow is also inversely 
proportional to the length of the tube, e.g. the longer the nasal cavity, the less the flow.  
The cross sectional area varies throughout the nose. It is smallest at the internal nasal 
valve, larger at the level of the turbinates, and largest at the level of posterior choana. Minimal 
changes in the cross sectional area of the internal valve may cause profound changes in 
airflow. Due to the changes in velocity and thus creation of turbulent airflow in different parts 
of the nose the nasal airflow is complicated to understand. The predominant flow is neither 
laminar nor turbulent, but a regime of varied disturbances which is termed transitional (47). 
The highest linear velocities are detected at the minimum cross sectional area (MCA) in the 
nasal valve region, reaching 12-18 m/s during normal breathing, whereas lowest velocities are 
in the olfactory region (47, 48). 
The nasal airflow is constantly changing due to variations in mucus, cilia, 
vasoconstriction and vasodilatation, reflexes, and the nasal cycle, figure 4. The latter implies 
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 spontaneous and often reciprocal change in unilateral nasal airflow due to congestion and 
decongestion of the nasal venous sinuses every 3-7 hours. During a normal cycle, one nasal 
cavity is assumed to be in a “working phase”, while the opposite cavity is in a “resting phase” 
which allows restoration of the mucosa. The associated subjective feelings of nasal 
patency/obstruction as well as the objective assessments of nasal patency are not merely a 
question of the nasal resistance. The occurrence of turbulences is of importance too. 
 
 
Figure 4. Diagram of the nose. The compliant wall of the nasal vestibule is supported by the alae nasi 
muscles. The nasal valve is at the level of the anterior tip of the inferior turbinate. The diagram illustrates the 
normal asymmetry of nasal congestion, with one side of the nose congested due to swelling of the venous sinuses 
in the nasal turbinates and the other side open and decongested due to constriction of the venous sinuses. The 
degree of congestion of the tip of the inferior turbinate determines the dynamic cross-sectional area of the nasal 
valve area and nasal airway resistance. Printed with permission from Eccles (26), slightly modified. 
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  NO is a gas which is continuously produced in the paranasal sinuses. In healthy 
controls at rest, almost all NO found in exhaled air originates from the upper airways with 
only a minor contribution from the lower respiratory tract and the lungs (49, 50). The 
involvement of autogenous NO in regulation of pulmonary function, as an enzymatically 
produced airborne messenger, is termed "aerocrine" (51). The high local NO concentrations in 
the nasal airways and the sinuses may help to protect against airborne infectious agents. Thus, 
the ﬁnding of low nasal NO levels in patients with chronic sinus disorders such as 
Kartagener’s syndrome and cystic ﬁbrosis may be used to facilitate early diagnosis of these 
two respiratory disorders (52).  
The olfaction monitors the intake of (noxious and non-noxious) airborne agents into 
the human respiratory system, and determines to a large degree the flavor and palatability of 
foods and beverages. It can also protect the lower airways by warning the subjects of several 
irritants and includes conscious and non-conscious responses of defense (53). The olfactory 
mucosa consists of pseudostratified columnar epithelium which covers the cribriform plate, 
the superior septum and sectors of both the superior and middle turbinates in both nasal 
cavities (54). Humans can detect more than 10000 different odors and discriminate between 
5000 odors (38). Patients with nasal polyps and symptoms of nasal blockage experience an 
impaired sense of smell (55). 
 
1.1.2.2 Middle airway 
The adenoids, the paired tubal tonsils, the lingual tonsils and the paired palatine tonsils 
are all secondary lymphoid organs belonging to the mucosa-associated lymphoid tissue 
(MALT), and due to the anatomical location, they are continuously exposed to foreign 
airborne and ingested antigens (56, 57). The larynx is involved in voice production, 
respiration and protecting the trachea from food aspiration. 
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 1.1.2.3 Lower airway 
The cardinal function of the lung is gas exchange. The lung also metabolizes 
compounds like angiotensin, serotonin and leukotrienes, filters small blood thrombi from the 
circulation, and acts as a reservoir for blood. The number of conducting airways, i.e. bronchi 
and bronchioles, is complete at birth and thereafter only increases in size (58). The function of 
the conducting airways is to lead inspired air to the gas-exchanging regions of the lung. From 
birth until 3 years of age, lung volume increases mainly due to an increasing number of 
alveoli, and alveoli may develop until the age of 8 years (59). The functional residual capacity 
increases from about 80 mL at birth to 3000 mL in the adult (60), and lung weight increases 
from 60 to 750 g (61). The major portion of this growth affects the respiratory zone, and most 
alveoli (85%) are added through multiplication after birth. There is an increase in lung 
parenchyma between the age of 1 month and 7 years by a factor of about 13, whereas the 
increase slows down until the age of 18 years (62). Later in life, the increase in lung volume is 
mainly due to expansion of alveoli. When the alveolar number is reduced or the physiological 
demands are increased, an even greater enlargement of alveoli may take place. Lung size 
increases at least until growth of the chest wall is complete (58).  
During inspiration, the volume of the thoracic cavity increases, and air is drawn into 
the lung due to the low intra thoracic pressure. The lung is elastic and returns passively to its 
pre-inspiratory volume during breathing at rest. Gas movement in the alveolar region is 
chiefly by diffusion. Blood spends about 0.75 second in the capillary at rest. The area of the 
blood-gas barrier in the lung is enormous (50 to 100 square meters), and the thickness is 
0.3μm in many places, so the barrier for diffusion is ideal. CO2 diffuses about 20 times more 
rapidly than O2 through tissue sheets because it has a much higher solubility.  
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 The exhaled volume after a maximal expiration is called the vital capacity. Some gas 
remains in the lung after a maximal expiration, and this is the residual volume. The volume of 
gas in the lung after a normal expiration is the functional residual capacity. 
The four causes of low oxygen concentration in blood, hypoxemia, are 
hypoventilation, diffusion limitation, shunt, and ventilation-perfusion inequality. Shunt is the 
only cause of hypoxemia in which the arterial PO2 does not rise to the expected level when a 
patient is given 100% O2 to breathe. Ventilation-perfusion inequality reduces the gas 
exchange efficiency of the lung for all gases, which means that the matching of ventilation 
and blood flow is disturbed. 
 NO is also produced by the lungs and is present in exhaled breath. Patients with 
asthma have high levels of NO in their exhaled breath and high levels of inducible nitric oxide 
synthase (NOS2) enzyme expression in the epithelial cells of their airways, suggesting a role 
for NO in asthma pathogenesis (63). Thus the concentration of NO in exhaled air increases in 
airway inflammation, but the interpretation can be difficult because of confounding factors 
such as height, age, gender, lung function, smoking, and respiratory tract infections, as further 
described in section 1.4.2 Objective measures of the unified airway. 
. 
1.1.2.4 Mucosa-associated defenses  
The airway mucosa has nonspecific defense mechanisms against pathogens that 
include the normal flora of microbes, the mucociliary system, and a specific immunological-
based defense system. 
 
The mucociliary system 
The mucociliary system serves as a mechanical, chemical and biological barrier 
between the respiratory epithelium in the nose and lungs and the pathogens encountering the 
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 airway. Nasal mucus provides a continuous layer in the nasal cavity in which particles in the 
turbulent airstream can impact and stick. The layer of mucus is moved by the coordinated 
waves of cilia from the anterior part of the nose to the nasopharynx, where it is swallowed or 
expectorated. Large particles are filtered out in the nose. Smaller particles that deposit in the 
conducting airways are removed by a moving staircase of mucus that continually sweeps 
debris up to the epiglottis, where it is swallowed (64). Mucociliary transport is disturbed in a 
variety of conditions which affect the activity of the cilia and the composition of the 
secretions, e.g. viruses, bacteria, cystic fibrosis, primary ciliary dyskinesia, Young’s 
syndrome and Kartagener’s syndrome. 
The specific, immunological based defense system 
The immune system is usually divided in an innate and an adaptive branch, both 
providing both humoral and cellular based defense mechanisms (figure 5). 
 
Figure 5. The immune system. Adapted from the thesis of Jesper Bogefors. 
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 The innate immune system is characterized by rapid onset, lack of specificity, limited 
diversity and no immunological memory. The innate humoral defense is mediated by 
bioactive molecules, like pattern-recognition receptors, antimicrobial peptides and the 
complement system. Cellular components of the innate immune system are granulocytes 
(neutrophils, basophils, and eosinophils), mast cells, dendritic cells and macrophages. These 
cells are armed with non-specific pattern recognition receptors that trigger the activation of 
defense mechanisms and stimulate the adaptive immune system (65, 66). Airway secretions 
contain innate immune defense proteins, including lysozyme, lactoferrin, human β-defensin 
and secretory leukocyte protease inhibitor, which form an important component of innate 
immunity against inhaled antigens and micro-organisms (67). The alveoli have no cilia, and 
particles that deposit there are engulfed by macrophages. The foreign material is then 
removed from the lung via the lymphatic system or the blood flow (64).  
The adaptive part requires some days to develop, is antigen specific, involves 
lymphocyte interactions, has a long lasting memory, and a marked diversity. It has great 
abilities of memory and protects the host from reinfections (68, 69). The T- and B 
lymphocytes constitute the cornerstone of the adaptive immune system, and are responsible 
for the cell mediated- and the humoral responses. Components of the adaptive immune system 
are found in nasal secretions and contain immunoglobulins IgA, IgG, IgM, IgE, where 
secretory IgA is the predominant immunoglobulin in mucosal tissues (70, 71). 
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 1.2 The Unified Airways in disease  
1.2.1 Pathophysiological pathways 
During the past two decades we have acquired a growing amount of evidence of a 
pathophysiological link between the upper and lower airways constituting a substantial 
foundation for the Unified Airway concept (72-74). The upper and lower airways share the 
same mucosal susceptibility to inhaled substances, and in clinical practice the upper and lower 
airways should be treated as one entity. Thus, several proposed mechanisms have been 
offered to explain the Unified Airway model, and so far four main pathophysiological 
pathways are considered of importance. 
The mechanism of primary interest is the one of shared inflammation (19, 20), where 
inflammatory processes can progress from one portion of the respiratory system to another 
called inflammatory cross talk. Thus disorders of the respiratory mucosa often present with a 
similar inflammatory response, which is common to diseases such as rhinitis, rhinosinusitis, 
and asthma (75). This inflammatory response has been demonstrated by Braunstahl and 
colleagues (18) who have shown that stimulation of one portion of the airway mucosa with 
antigen will result in system-wide inflammatory changes within a matter of hours. Thus 
placement of antigen directly onto the bronchial mucosa using bronchoscopy has been shown 
to induce nasal inflammation in patients who have allergic rhinitis. In addition, reciprocal 
induction of bronchial inflammation with nasal antigen stimulation has been demonstrated 
using a similar model (19). Moreover, experimental studies have shown that stimulation with 
antigen at one respiratory site can result in expression of inflammatory cytokines at a distant 
location (18, 19, 76, 77). 
A second proposed mechanism is the presence of a nasobronchial reflex where 
inflammatory conditions, chemical, thermal, and biological irritants in the nasal mucosa might 
generate nerve impulses which trigger bronchoconstriction. Kaufman and Wright (78) 
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 performed a study where silica particles were applied directly to the nasal mucosa in subjects 
without asthma. Measurement of pulmonary function in these subjects was reported to 
demonstrate rapid and significant increases in lower airway resistance, leading to the 
speculation that a direct reflex was stimulated between the nose and the lungs. Subsequent 
studies showed that this effect could be blocked through the administration of atropine (78) or 
with resection of the trigeminal nerve (79). Additional support for this presumed 
nasobronchial reflex has not been demonstrated, as other studies have failed to replicate the 
effects of nasal stimulation in causing rapid bronchoconstriction (80-82). In animal models 
where nasal stimulation has been conducted with thermal, chemical, and  mechanical stimuli, 
no reflex changes in ventilation or oxygenation have been demonstrated (83). Delayed 
changes can be seen in the lung from 30 minutes to four hours after antigen challenge of the 
nose (84), but immediate reflex changes in pulmonary function cannot be demonstrated 
consistently. These findings suggest that mechanisms other than a direct reflex arc may be 
responsible for the observed relationship between upper and lower airway disease (74).  
A third proposed mechanism is oral breathing and consequently a loss of nasal 
protection of the lower airway. Shturman-Ellstein and colleagues (85) performed in 1978 a 
study where patients who had exercise-induced asthma were allowed to exercise under three 
conditions: spontaneous breathing, nasal breathing, and mouth breathing. This study 
demonstrated that mouth breathing seemed to worsen bronchospasm and nasal breathing 
appeared to have a protective effect. Thus nasal breathing is suggested to have a beneficial 
effect on the lower airway through the conditioning of inspired air for delivery to the lungs. It 
is also shown that asthmatics switch to oral breathing at a significantly lower nasal load 
compared to healthy controls (86).  
A fourth proposed mechanism is aspiration of nasal secretions into the lower airways. 
Sino nasal infections may disperse to the lower airways in patients with impaired cough reflex 
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 and reduced mucociliary clearance, e.g. progressive neurodegenerative conditions, cystic 
fibrosis and intensive care unit patients on ventilatory support. Thus, optimization of the nasal 
function may prevent lower respiratory infections. However, in healthy individuals, seeding 
of mucopurulent secretions into the lower airways is unlikely to account for coexistent 
pulmonary disease (87).  
 
1.2.2 Allergy 
Allergy is defined as an abnormal adaptive immune response directed against non-
infectious environmental substances (allergens), including non-infectious components of 
certain infectious organisms. In allergic disorders, such as anaphylaxis, allergic rhinitis, some 
food allergies and allergic asthma, these responses are characterized by the involvement of 
allergen-specific IgE and T helper 2 (Th2) cells that recognize allergen-derived antigens (88). 
The diagnosis of allergy is based upon the concordance between a typical history of allergic 
symptoms and diagnostic tests. 
Allergy is a multifactorial disease induced by interaction between host- and 
environmental factors. Host factors include heredity, sex, race and age. Environmental factors 
include exposure to allergens, smoking, pollution and infections.  
Allergic rhinitis and allergic asthma are characterized by similar inflammatory 
processes, which is a result of subsequent events which can be divided in to an early phase 
and a late phase of the allergic response. The early phase starts with an IgE-mediated type I 
immediate hypersensitivity reaction that can occur within minutes of allergen exposure and is 
characterized by vasodilation, increased vascular permeability, vascular leakage and oedema. 
In such reactions, IgE bound to mast cells and basophils is cross linked by allergen, resulting 
in the release of preformed and newly synthesized mediators (88). Some of the released 
mediators also promote the local recruitment and activation of leukocytes, contributing to the 
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 development of late-phase reactions. Antigen presenting cells (APC), present in the 
superficial areas of the skin and mucosa of the airways engulf antigen. The APC migrate to 
lymph nodes where the antigen stimulates T- and B- lymphocytes. The T-lymphocyte 
recognizes fragments of antigen bound to the major histocompatibility complex molecules 
expressed on the surface of the APC. The B-lymphocyte recognizes antigen through their 
immunoglobulin receptors and develops into plasma cells, which produce specific IgE 
antibodies that bind to mast cells. Subsequent exposure to allergen results in cross binding of 
specific IgE on mast cells leading to a degranulation with the release of histamine and 
proteases. The activation of the T-cell receptor stimulates the naïve T-helper cell which 
differentiates to either Th1 or Th2 cells, with the following secretion of interferon gamma and  
interleukins IL-2 (Th1), IL-4, IL-5, IL-9, IL-13 (Th2), IL-3 and Granulocyte-macrophage 
colony-stimulating factor (both Th1 and Th2) (89). Tissue eosinophilia is a characteristic 
feature of the late phase reaction, which occurs about four to ten hours (with a maximum after 
7-8 hours) after exposure. The eosinophil is a source of leukotrienes, prostaglandins, platelet 
activating factors, cytokines and cytotoxic proteins, which can be released upon stimulation 
and are toxic to the airway epithelium. When the allergic stimulus is continuously present, or 
other noxious stimuli appear in the environment of the patient, the allergic inflammation 
process may become chronic (88). A common feature of chronic allergic inflammation is 
tissue remodeling (90). 
 
1.2.3 Upper airway 
Nasal blockage can be defined as discomfort due to insufficient airflow through the 
nose. In the literature many synonyms of nasal obstruction are used like nasal stuffiness, nasal 
blockage and nasal congestion (91). In this document nasal obstruction also includes the terms 
nasal blockage and nasal stuffiness, whereas nasal congestion describes the reduced airflow 
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 due to mucosal congestion (92, 93). The prevailing reading in literature of nasal patency is 
that it characterizes an objective measure of how open the nose is. 
The etiology of nasal obstruction may be structural, mucosal or functional/subjective.  
Structural causes of airflow limitation include abnormalities of the cartilaginous and/or bony 
constituents of the nose, congenital or acquired, unilateral or bilateral. Septal deviation is 
common, with a prevalence ranging from 19.4% to 65%, due to different criteria for defining 
a deviated septum (94, 95), but its clinical significance is questionable because it’s a frequent 
finding in many asymptomatic individuals (96). Septal perforation probably affects 0.9% of a 
population (97) and often causes symptoms like crusting, bleeding, nasal obstruction, 
whistling and pain. Almost 40% of septal perforations are completely asymptomatic (98). 
Enlargement of the inferior turbinate may be caused by osseous thickening of the bone core 
with cellular hypertrophy- and hyperplasia. Unilateral enlargement is frequently associated 
with deviation of the septum  into the contralateral nasal passage (99). Enlargement of the 
middle turbinate due to a concha bullosa is a frequently encountered anatomic variant, often 
associated with septal deviation, and may have the potential to occlude the middle meatus and 
predispose to inflammation of the paranasal sinuses (100, 101). Other structural causes are 
adenoidal hypertrophy, anatomical variants in the osteomeatal complex, foreign bodies and 
choanal atresia (102).  
Mucosal causes consist of congestion and inflammation caused by allergic- and non-
allergic rhinitis, nasal polyposis, turbinate enlargement, drug reactions, endocrine or 
metabolic conditions, systemic inflammatory and granulomatous conditions like sarcoidosis 
and granulomatosis with polyangiitis, and ciliary defects. According to the Allergic Rhinitis 
and its Impact on Asthma (ARIA) 2008 Review (102) rhinitis can be classified as: Infectious 
(viral, bacterial or other), allergic (intermittent or persistent), occupational (intermittent or 
persistent), drug induced, hormonal, other causes like NARES (non-allergic rhinitis with 
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 eosinophilia syndrome), irritants, food, emotional, atrophic and idiopathic. Turbinate 
enlargement can be bilateral, caused by nasal inflammations such as allergic and non-allergic 
rhinitis, environmental triggers e.g. dust, tobacco smoke, medication, and medical causes 
including pregnancy. Asthmatic patients have more concomitant chronic rhinosinusitis (CRS) 
with nasal polyps (CRSwNP) (7 %) than the general population (4 %) (103). In non-atopic 
asthma and late-onset asthma, CRSwNP was found even more frequently (104). On the other 
hand, more than 60 % of CRSwNP patients have lower airway involvement (105). 
Mechanisms causing inferior turbinate enlargement are mucosal, with dilatation of venous 
sinuses, tissue oedema, cellular hypertrophy and cellular hyperplasia (99). 
Functional causes may be present without any obvious airflow restriction. Such 
conditions include atrophic rhinitis and empty nose syndrome following radical endonasal 
surgery or trauma. The lack of obvious pathology in some obstructed noses might be 
explained by the disruption of normal airflow patterns (106, 107), impaired mucosal sensation 
(26, 108, 109), and psychological and other non rhinological factors such as individual 
differences in symptom perception, interpretation and symptom mastering which may 
influence the subjective outcome (26, 110). Nasal obstruction may be the presenting symptom 
in a large variety of conditions, some of which is presented in figure 6. 
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Figure 6. The different etiologies of nasal airway obstruction which may be polyfactorial. Modified from 
Chandra (106). 
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 1.2.4 Middle airway 
In children, enlarged tonsils and/or adenoids may cause Eustachian tube 
dysfunction/otitis media, rhinosinusitis, obstructive sleep apnea, voice changes, change in 
facial growth, swallowing problems and can affect overall quality of life.  
Enlarged adenoids can obstruct the nasal passageway and it is shown that children 
with asthma have a larger nasal-adenoid index than controls (111). 
Laryngopharyngeal reflux may present with asthma like symptoms. Accumulating 
evidence suggests a strong association between gastroesophagal reflux disease (GERD) and 
pulmonary diseases, including adult-onset asthma. The prevalence of GERD in patients with 
asthma has been reported to range from 30% to 90% (112, 113). 
 
1.2.5 Lower airway 
Bronchial responsiveness (BR) may be defined as a tendency of the airways to 
constrict to a variety of physical or chemical stimuli. Bronchial hyperresponsiveness (BHR) is 
present when the degree of BR is greater than that observed in normal subjects, but the 
distinction between normal and heightened BR is not sharp. BHR is linked to both 
inflammation and repair of the airway and is partially reversible with therapy. Inflammatory 
changes in the airway wall may lead to excessive narrowing of the airways. Thickening of the 
airway wall by edema and structural changes amplifies airway narrowing due to contraction 
of airway smooth muscles for geometric reasons (114). Sensory nerves may be sensitized by 
inflammation, leading to exaggerated bronchoconstriction in response to sensory stimuli. 
The Global initiative for asthma (GINA (17) defines asthma as a chronic inflammatory 
disorder of the airways in which many cells and cellular elements play a role. The chronic 
inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes 
of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early 
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 morning. These episodes are usually associated with widespread, but variable, airflow 
obstruction within the lung that is often reversible either spontaneously or with treatment (17).  
The etiology of asthma is complex, but can be divided into host factors and 
environmental factors. Host factors include genes, obesity and sex. Multiple genes may be 
involved in the pathogenesis of asthma (115, 116) and different genes may be involved in 
different ethnic groups. Asthma is observed more frequently in obese subjects (body mass 
index (BMI) > 30 kg/m²) and is more difficult to control (117). Male sex is a risk factor for 
asthma in childhood. Prior to the age of 14, the prevalence of asthma is nearly twice as great 
in boys as in girls (118). Environmental factors include allergens, infections, occupational 
sensitizers, tobacco smoke, outdoor/indoor air pollution and diet. Indoor (domestic mites, 
furred animals, cockroach allergen, fungi, molds, yeasts) and outdoor (pollens, fungi, molds, 
yeasts) allergens are known to cause exacerbations, but their specific role in the development 
of asthma is not fully resolved (17). For some allergens, such as those derived from house 
dust mites and cockroaches, the prevalence of sensitization appears to be directly correlated 
with exposure (119). Some epidemiologic studies have found that early exposure to dogs and 
cats may protect a child against allergic sensitization or the development of asthma (120), but 
others suggest that such exposure may increase the risk of allergic sensitization (121). The 
“hygiene hypothesis” of asthma suggests that exposure to infections early in life influences 
the development of a child’s immune system along a “non-allergic” pathway, leading to a 
reduced risk of asthma and other allergic diseases. Although the hygiene hypothesis continues 
to be investigated, this mechanism may explain observed associations between family size, 
birth order, day-care attendance, and the risk of asthma (17). Further, over 300 substances 
have been associated with occupational asthma, which is defined as asthma caused by 
exposure to an agent encountered in the work environment (17). Tobacco smoke is associated 
with accelerated decline of lung function in people with asthma (122), increases asthma 
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 severity, may render patients less responsive to treatment with inhaled (123) and systemic 
(124) glucocorticoids (GC), and reduces the likelihood of asthma being controlled (125). The 
role of outdoor air pollution causing asthma remains controversial (126). Outbreaks of asthma 
exacerbations have been shown to occur in relationship to increased levels of air pollution, 
and this may be related to a general increase in the level of pollutants or to specific allergens 
to which individuals are sensitized (127). The same has been observed in relation to indoor 
pollutants, e.g., smoke and fumes from gas and biomass fuels used for heating and cooling, 
molds, and cockroach infestations. The role of diet, particularly breast feeding, in relation to 
the development of asthma has been extensively studied. Data reveal that infants fed formulas 
of infants cow’s milk or soy protein have a higher incidence of wheezing illnesses in early 
childhood compared with those fed breast milk (128). 
Several factors contribute to the development of airway narrowing in asthma: airway 
smooth muscle contraction, airway edema due to increased microvascular leakage in response 
to inflammatory mediators, airway thickening due to structural changes such as remodeling, 
and mucus hyper secretion leading to luminal occlusion. The characteristic structural changes 
in the airways, described as airway remodeling, include the increase in airway smooth muscle, 
both as hypertrophy and hyperplasia, proliferation of blood vessels, increased numbers of 
goblet cells and increased size of submucosal glands, and subepithelial fibrosis due to 
deposition of collagen fibers and proteoglycans under the basement membrane (17). 
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 1.3 Treatment in a Unified Airway perspective 
Avoidance of allergens is of uttermost importance in the treatment of upper, middle 
and lower airway symptoms. Indoor and outdoor allergens should be identified and avoided.   
1.3.1 Medical treatment  
1.3.1.1 Upper airways 
The medical treatment of nasal obstruction involves several therapies. The mechanism 
of saline nasal irrigation depends mainly on washing away allergens and inflammatory 
mediators induced by allergic reactions (129), remove bacteria, bacterial pus debris (130) in 
rhinosinusitis, and after nasal surgery. It has been shown that daily nasal saline irrigation 
improves symptoms and reduces the need for medical therapy in CRS and sinonasal disease 
(131, 132). 
Nasal decongestants are fast acting topical vasoconstrictive drugs acting by stimulating the 
adrenergic alpha-receptors, effective for the reduction of nasal congestion on a short time 
basis (133). They can be classified into two major groups: (1) sympathomimetic amines 
(cocaine, amphetamine, adrenaline, and ephedrine) and (2) imidazolines (oxymetazoline and 
xylometazoline). Of the imidazolines, oxymetazoline, a selective α-1 and partial α-2 agonist, 
and xylometazoline, an α-2 agonist, are the most popular and clinically used derivatives. The 
main side effect of topical decongestants is the development of rhinitis medicamentosa, which 
may appear in some patients after only 3 days. European guidelines recommend a maximum 
of 10 days use (134). Oral decongestants usually contain pseudoephedrine, or phenylephrine. 
Topical- and oral decongestants are not recommended for use in acute and CRSwNP and 
chronic rhinosinusitis without nasal polyps (CRSsNP) (135). 
Oral antihistamines are classified as first, second and third generation. The first generation 
H1antihistamines such as alimemazin, deschlorpheniramine and prometazin are effective at 
controlling the rhinorrhea, sneezing and pruritus associated with rhinitis, but unfortunately 
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 these agents cross the blood-brain barrier, thus producing undesirable side effects such as 
central nervous system depression, sedation leading to impaired performance at home, work 
and school as well as cardio toxicity. The second-generation antihistamines, such as cetirizin, 
ebastin, fexofenadin, and loratadin have improved H1 receptor selectivity, faster onset and 
longer duration of action and fewer adverse effects. Their half-lives are longer (12-24 hours) 
compared to the first generation (4-12 hours) (136). Both second and third generation, such as 
desloratadin and levocetirizin, have all anti-allergic and anti-inflammatory properties. Topical 
antihistamines have been found to be very effective for the overall treatment of allergic 
rhinitis (137).  
Glucocorticosteroids (GC) exert anti-inflammatory effects on the nasal mucosa mediated by 
inflammatory cells such as eosinophils, T helper type 2 (Th2) cells, mast cells, B cells, 
dendritic cells and basophils, and also by nasal constitutive cells such as epithelial cells, 
endothelial cells, fibroblasts and glands/goblet cells. Treatment with GC can also induce 
regulatory T cells. Further, GC exert regulatory functions by inducing regulatory cytokines 
and regulatory T cells. Although GC are highly effective in mitigating inflammation, their 
potent action potentially causes severe adverse effects. To decrease this risk, intranasal 
glucocorticosteroid formulations (INS) with low systemic availability have been developed 
for the treatment of allergic rhinitis. INS (drops or spray) are also the primary medical 
treatment for CRSwNP and CRSsNP. The efficacy of INS in reducing nasal symptoms and 
reducing polyp size has been demonstrated in many randomized controlled trials (138, 139). 
Epistaxis, dry nose, nasal burning and nasal irritation are considered to be drug-related events 
(135). Oral corticosteroids may be administered as rescue therapy only in cases of patients 
affected by severe symptoms, in particular nasal obstruction, not controlled by other 
treatments (140). 
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 Antibiotics are not indicated in the treatment of rhinitis and of rhinosinusitis without 
complications.  
Leukotrienes are metabolites of cellular arachadonic acid and contribute to smooth muscle 
contraction, eosinophilic inflammation and mucus production. Antileukotrienes (Singulair®) 
are viewed as add-on or second-line therapy in current guidelines for the treatment of asthma 
and rhinitis/rhinosinusitis (141, 142). 
Anti-reflux medication could be considered as an option in patients with asthma and CRS, 
particularly in those where conventional medical and surgical treatment is insufficient (143). 
Intranasal chromones (disodium cromoglycate (Lomudal Nasal®)) stabilize mast cells and 
may improve nasal symptoms by reducing the synthesis and release of mediators such as 
histamine, leukotrienes and tryptase. They are able to inhibit both early and late phase of the 
allergic reaction, but they need several applications (three or four times daily) and have a 
weaker effect on allergic rhinitis symptoms compared with other drugs (144). 
Combination therapy with different drugs, with different mechanisms of action, may 
provide an additional and synergistic beneficial effect. A novel combination therapy with 
azelastine hydrochloride and fluticasone propionate nasal spray in a single device is now 
available (Dymista®). 
Omalizumab (Xolair®) is a recombinant humanized anti-IgE antibody that blocks the 
interaction of IgE with mast cells and basophils, which is approved for the treatment of severe 
persistent allergic asthma. IgE play a central role in the pathogenesis of allergic rhinitis and its 
efficacy has been evaluated in patients with allergic rhinitis where a clinical benefit was 
reported (145, 146). 
Specific immunotherapy (SIT) like subcutaneous immunotherapy and sublingual 
immunotherapy are established methods of disease modifying treatments of allergic rhinitis 
and asthma (147). Future routes for the administration of SIT include intralymphatic 
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 immunotherapy and epicutaneous immunotherapy, which exploit the high density of dendritic 
cells and the low numbers of mast cells and basophils in lymph nodes and skin, respectively, 
thus facilitating antigen presentation and  minimizing side effects such as anaphylaxis (148, 
149). 
Histamine H4 receptor antagonists, Phosphodiesterase 4 inhibitors, mast cell activity 
inhibitors and targeted treatment towards the toll-like receptors may in the future be available 
for the treatment of allergic rhinitis (150). Cytokines are important in the pathogenesis of 
allergic inflammation and their inhibition is thus considered a possible pathway for the future 
treatment of allergic rhinitis (151). 
 
1.3.1.2 Middle airways 
Antibiotics are used for the treatment of tonsillitis caused by streptococci or in cases 
with more severe or prolonged disease. 
Acid reflux medication for GERD includes antacids, histamine type 2 receptor 
antagonists and proton pump inhibitors. 
 
1.3.1.3 Lower airways 
Medications to treat asthma can be classified as controllers or relievers. Asthma 
medication can be administrated by inhalation, orally and by injection. 
Controllers  
Controllers are medication taken daily on a long term basis to keep asthma under a 
clinical control mainly through their anti-inflammatory effects. Inhaled GC are the most 
effective controller currently available. Systemic glucocorticoids, long-acting inhaled β2 
agonists in combination with inhaled GC, leukotriene modifiers, sustained-release 
theophylline and anti-IgE are alternatives (17). 
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 Relievers 
Relievers are medication that acts quickly to reverse bronchoconstriction and relieve 
symptoms, usually used on an as-needed basis. They include short and long acting inhaled β2 
agonists with rapid to delayed onset, inhaled anticholinergics, sustained release theophylline 
and oral β2 agonists (17).  
 
1.3.2 Surgical treatment 
Surgery on inferior turbinates is performed when turbinate enlargement is present 
and conservative treatment fails either solitary or in combination with septal surgery (110). 
Turbinate reduction can be done by several techniques such as submucosal diathermy, 
cryosurgery, laser cautery, radiofrequency thermal ablation and coblation (152). The turbinate 
resection can be partial, total, or submucosal (99).  
Septoplasty can be performed when septal deviation and symptoms of nasal obstruction are 
present (96).  
Correction of collapse of the nasal valve is performed when nasal valve dysfunction or 
collapse is present (153). Several surgical techniques have been described with strengthening 
and opening maneuvers. This often involves simultaneous surgery on the nasal septum and 
inferior turbinates.  
Surgery of the nasal tip is performed for cosmetic reasons and/or to improve subjective and 
objective nasal airflow (154). 
Functional endoscopic sinus surgery (FESS) is performed to re-establish ventilation and 
drainage between the sinuses and nasal cavity through the natural ostia of the sinuses. Most 
surgical procedures start with removal of the uncinate process to facilitate access to the 
middle meatus, followed by antrostomy to the maxillary sinus, anterior ethmoidectomy, 
posterior ethmoidectomy, frontal recess surgery, sphenotomy and surgery on concha bullosa. 
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 The surgical procedure depends of the type and extent of disease. Removal of polyps is also 
essential to re-establish ventilation and drainage of the sinuses.  
Tonsillectomy and/or adenoidectomy are among the most common surgical procedures in 
children. Adenotonsillectomy in patients with asthma can reduce their respiratory symptoms 
and doses or frequency of medications (155, 156).  The effect of adenoidectomy alone on 
asthma is not yet scientifically documented. 
1.3.3 Mechanical dilatators  
External dilator Breath Right® is a non-invasive mechanical device aimed to facilitate 
nasal breathing. It is a spring-loaded plastic strip that by adhesion to the skin overlying the 
compliant soft tissues of the anterior nose dilates the vestibular lumen. Nozovent is a device 
made of plastic which is placed in the nostrils and widens them so that nasal airflow is 
increased. 
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 1.4 Methods to measure symptoms and functions of the Unified 
Airway 
As early as 1895 the rhinologist Kayser described the core challenges in rhinology in a 
captivating way: “Although in most cases its seems easy to determine a complete occlusion of 
the nose during an examination, in many cases it is difficult to translate this objective finding 
into an assessment as to whether the narrowing of the nasal passages actually impairs the 
respiratory function of the nose. It is therefore important to be able to perform a functional 
examination of the nose, i.e. determine whether the flow of air through a particular nose (e.g. 
that of the patient) is normal. Only the demonstration of a functional insufficiency of the nose 
can give our therapeutic intervention greater accuracy, and only in this way can we 
demonstrate any effects of this intervention in an objective manner. After all, we measure the 
acuity of the eye and the hearing ability of the ear” (157). 
 
1.4.1 Subjective measures of the unified airway 
Symptom assessment of the unified airway is obviously of central importance, thus 
giving exclusive information about the patient’s understanding of the disease and often 
dictates the need of intervention.  
Visual analog scales (VAS) are quantitative measures thoroughly validated in many diseases 
(158, 159). These scales have been extensively used to assess the severity of rhinitis as well as 
the efficacy of therapeutic interventions (160).  
The Asthma Control Questionnaire (ACQ) is a validated disease-specific test used for 
evaluation of asthma symptoms (161) where the patients are asked to recall on a 7-point scale 
(0=no impairment, 6= maximum impairment) how their asthma has been during the last week. 
  A disease specific quality of life assessment of the unified airways gives a tool to 
measure the overall effect of specific medical issues on a patient. 
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 The Sino-Nasal Outcome Test-20 (SNOT-20), and the modified versions SNOT 16 and  
SNOT 22 are validated disease-specific quality-of-life (QoL) questionnaires for rhino-
sinusitis (162). The Nasal Obstruction Symptom Evaluation Scale (NOSE) (163) and Rhinitis 
quality of life questionnaire (164) are similar disease-specific health status instruments for use 
in patients with nasal obstruction. There are many similar asthma specific health status 
instruments, e.g. Asthma Quality of Life Questionnaire, Standardized Asthma Quality of Life 
Questionnaire, Mini Asthma Quality of Life Questionnaire, Asthma Quality of Life 
Questionnaire for 12 years and older, and Acute Asthma Quality of Life Questionnaire.  
 
1.4.2 Objective measures of the unified airway 
Peak nasal inspiratory flow (PNIF) is a noninvasive method used to assess nasal 
patency. It is a physiological measure obtained during maximal inspiration and indicates the 
peak nasal airflow in liters per minute. No information is obtained regarding the structure of 
the nose or the location of nasal obstruction with PNIF, as is the case with acoustic 
rhinometry. 
Acoustic rhinometry (AR) is a sonic echo technique, where the nasal airway is measured 
noninvasively by cross-sectional area as a function of longitudinal distance along the nasal 
passage. Nasal passage volumes are calculated from contiguous cross-sectional values. The 
technique is highly reproducible and exhibits its greatest accuracy in the anterior nose where 
the nasal valve is located (30, 165, 166). It is a static test conducted during breath-holding. 
AR is unaffected by airflow pressures on compliant nasal tissues and cannot detect nasal 
valve collapse that occurs only on inspiration.  
Flow volume spirometry is a measure of the speed (flow) and amount (volume) of air that 
can be inhaled and exhaled. Most spirometers display a flow-volume loop, which graphically 
depicts the rate of airflow on the Y-axis and the total volume inspired or expired on the X-
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 axis, and a volume-time curve, showing volume (liters) along the Y-axis and time (seconds) 
along the X-axis. There are two categories of bronchial provocation tests, “direct” and 
“indirect”. The “direct” category includes the pharmacological agents histamine and 
methacholine. This is a medical test where methacholine and histamine are used to assist the 
diagnosis of bronchial hyperreactivity and asthma. Both drugs provoke bronchoconstriction, 
and people with pre-existing airway hyperreactivity, such as asthmatics, will react to lower 
doses of methacholine and histamine. The “indirect” challenge include the physical stimuli 
such as exercise, hyperpnoea of dry air, distilled water, hypertonic saline and mannitol, and 
the pharmacological agent adenosine monophosphate. These stimuli are thought to cause 
airway narrowing “indirectly” by releasing a wide variety of mediators of bronchoconstriction 
from inflammatory cells within the airway. These mediators act on specific receptors on 
bronchial smooth muscle to cause contraction, with airway narrowing as a consequence. 
NO can be measured in exhaled air from the lungs as fractional exhaled nitric oxide (FENO) 
which is a validated inflammatory marker in the diagnosis and management of patients with 
asthma, atopy, and allergic rhinitis (167). It is a useful, reproducible, noninvasive, easy to 
perform, and rapid tool (168). FENO offers added advantages for patient care including, but not 
limited to, detection of eosinophilic airway inflammation, determining the likelihood of 
corticosteroid responsiveness, monitoring of airway inflammation to determine the potential 
need for corticosteroid, and unmasking of otherwise unsuspected non adherence to 
corticosteroid therapy (168). The American Thoracic society recommends that FENO less than 
25 ppb (< 20 ppb in children) indicate that eosinophilic inflammation and responsiveness to 
corticosteroids are less likely. FENO greater than 50 ppb (> 35 ppb in children) indicate that 
eosinophilic inflammation and, in symptomatic patients, responsiveness to corticosteroids are 
likely, and lastly that FENO values between 25 ppb and 50 ppb (20–35 ppb in children) should 
be interpreted cautiously and with reference to the clinical context (168).   
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 Rhinomanometry is a method for the objective measurement of nasal airway resistance 
(NAR) during normal breathing. The measurements of NAR are performed by anterior 
(anterior nasal cavity), postnasal (posterior nasal cavity) or posterior (in the mouth) 
rhinomanometry, based on the patient’s own respiration (active method) or using flow 
generated externally (passive method). A newer development is the four phases 
rhinomanometry and resistometry (169).Rhinostereometry, manometric rhinometry, forced 
oscillation technique, and nasal spirometry are other methods for measuring nasal cavity 
dimensions, but the clinical and scientific uses of these are quite limited.  
Computational fluid dynamics (CFD) is a technology employed widely in engineering to 
solve and analyze problems that involve flow of fluids. CFD can be used to demonstrate 
physiological and pathophysiological airflow conditions in the nose and to do preoperative- 
and postoperative monitoring of surgical outcome (170). 
Digital particle image velocity (DIPV) is an experimental method used to evaluate airflow in 
an accurately reproduced transparent model of the nasal cavity. DIPV use the same principle 
as that of movement of dust particles which can be recognized in a sliver of sunlight passing 
through a window. This method uses optically transparent materials where the flow is seeded 
with tracer particles and is illuminated with a sheet of laser light, and thus creating models of 
nasal airflow.   
Sniffin' Sticks' is a test of nasal chemosensory performance based on pen-like odor 
dispensing devices. It comprises three tests of olfactory function; tests for odor threshold, 
odor discrimination and odor identification (171). 
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 2 Aims of the studies 
2.1 General aims: 
The overall aim of this thesis is to compare subjective and objective outcomes in noses 
of asthmatics compared to non-asthmatic controls. 
 
2.2 Specific aims: 
1: We aimed to investigate the association between subjective sino-nasal complaints, nasal air 
flow, and sino-nasal quality of life (QoL) in patients with asthma compared with non-
asthmatic subjects. 
2: We aimed to investigate nasal airway patency in asthmatics compared to non-asthmatic 
controls using AR and PNIF.  
3: We aimed to investigate the individual effects of a diagnosis of asthma and of lung function 
on PNIF when adjusted for possible confounders. Further, we investigated the perception of 
nasal obstruction in asthmatics compared to healthy controls when adjusted for PNIF.  
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 3 Materials and methods 
3.1 Study population 
This thesis is based on 3 cross-sectional studies with basis in registrations of 103 
asthma patients recruited from the Department of Thoracic Medicine, St.Olavs University 
Hospital, Trondheim, Norway, and 100 non-asthmatic control subjects. The controls were 
individuals recruited from businesses near by the hospital or patients attending the hospital for 
other illnesses, which were thought not to affect the upper and lower airways. 
The enrollment took place in the period from August 2009 to December 2010. All subjects 
gave written consent that they were participating in a study concerning the “upper and lower 
airways in asthmatics”, but were not informed further about the specific purposes of the study. 
Each individual followed the same standard assessment procedure according to study 
protocols. The research was approved by the Regional Committee for Medical Research and 
conducted according to the Helsinki Declaration.  
 
3.2 Inclusion and exclusion (figure 7) 
The asthma diagnosis was based on the presence of typical asthma symptoms, with 
either ≥ 12% and ≥ 200 ml improvement of forced expiratory volume in the first second 
(FEV1) from baseline after inhalation of salbutamol or positive methacholine bronchial 
provocation test (PD20 FEV1 ≤ 1600 mg) and in accordance with the British Thoracic Society 
criteria (172).  
In paper 1 exclusion criteria were pregnancy, a history of cancer, presence of acute 
and chronic rhinosinusitis (CRS), and nasal polyposis on otorhinolaryngological examination, 
previous nasal surgery, and systemic disease with potential affection of the nose, such as 
granulomatosis with polyangiitis (Wegener’s granulomatosis), cystic fibrosis, primary ciliary 
dyskinesia, Kartagener’s syndrome, and sarcoidosis. In paper 1 a total of 12 asthmatics and 5 
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 controls were excluded. The asthmatics were excluded due to (number in parenthesis): CRS 
(9) and septum perforation (3). The controls were excluded due to (number in parenthesis): 
CRS (2) and questionable pulmonary disease (3).  
In paper 2 and 3 the exclusion criteria were the presence of acute and chronic 
rhinosinusitis and nasal polyposis on oto-rhino-laryngological examination and in accordance 
to the EPOS 2012 criteria (135), pregnancy, previous nasal surgery, systemic disease with 
potential affection of the nose, such as granulomatosis with polyangiitis (Wegener’s 
granulomatosis), cystic fibrosis, primary ciliary dyskinesia, Kartagener’s syndrome and 
sarcoidosis, and a history of cancer. In paper 2 a total of 16 asthmatics and 7 controls were 
excluded and in paper 3 a total of 16 asthmatics and 8 controls were excluded. The asthmatics 
in paper 2 and 3 were excluded due to (number in parenthesis): CRS (9), septum perforation 
(3), missing decongested values (1), patient resistant to accept topical xylometazoline (1) and 
technical artefact AR (2). The controls in paper 2 were excluded due to (number in 
parenthesis): CRS (2), questionable pulmonary disease (3), and technical artefact AR (1) and 
alar insufficiency (1). In paper 3 the controls were excluded due to CRS (2), questionable 
pulmonary disease (3), technical artefact acoustic rhinometry (1), alar insufficiency (1), and 
missing value (1). 
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 Figure 7.  Flow chart over inclusion and exclusion for paper 1, 2 and 3.  
 
3.3 Recordings 
All questionnaires used in this thesis are presented in the Appendix. 
Visual analogue scale (VAS)  
 The degree of nasal obstruction, oral breathing, snoring, sleep apnea, nasal 
discharge/secretions, headache, mid facial pain, rhino-sinusitis, coughing, sneezing, reduced 
general health, and reduced sense of smell was assessed on a 100 mm Visual Analog Scale 
(VAS). The endpoints were 0 mm (never) and 100 mm (always).  
Quality of life 
SNOT-20 was used because it has been translated to Norwegian and validated by 
Kjærgaard and Steinsvåg. Subjects were asked to grade 20 items on a scale of 0 (no problem) 
to 5 (problem as severe as can be) on the SNOT-20. The SNOT-20 score for each subject was 
The nasal airway in asthmatics
103 asthmatics
100 controls 
Paper 1
Inclusion
91 asthmatics
95 controls
Exclusion
12 asthmatics
5 controls
Paper 2
Inclusion
87 asthmatics
93 controls
Exclusion
16 asthmatics
7 controls
Paper 3
Inclusion
87 asthmatics
92 controls
Exclusion
16 asthmatics
8 controls
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 defined as the mean value of the response to the 20 items. Furthermore, the SNOT-20 
questionnaire was divided into subscales based on the study of Browne et al (173). The first 
subscale was composed of questions about symptoms related to nose, ear, and face; the 
second subscale included the questions on psychological issues; and the third subscale 
addressed sleep function. Questions about cough and waking up tired are separate entities and 
do not belong to any subscale.  
Asthma control questionnaire (ACQ) 
Patients were asked to recall how their asthma had been during the previous week and 
to respond to the symptom (5 questions) and bronchodilator use questions on a 7-point scale 
(0=no impairment, 6= maximum impairment). In addition the clinic staff scored the FEV1% 
predicted on a 7-point scale. The questions are equally weighted and the ACQ score is the 
mean of the 7 questions ranging between 0 (totally controlled) and 6 (severely uncontrolled). 
Acoustic rhinometry 
We used an impulse Acoustic Rhinometer (RhinoMetrics SRE 2100, Rhinoscan 
Version, Interacoustics, Minneapolis, MN) which was handled by two trained operators 
throughout the studies in this thesis. Anatomic nose-pieces in two sizes and contact gel 
between the nose-piece and the nostril were used. The probe was hand held with the subject 
sitting upright opposite to the investigator holding the breath during the measurements.  
Recordings were performed according to published protocols (174).  
The values obtained by AR represent an average of 3 recordings from the right and left 
nasal cavity, which were averaged to get an overall mean value due to the variations 
represented by the nasal cycle. The following measures were recorded; minimal cross 
sectional area (MCA) in cm² from 0 to 3 cm (MCA0-3), 3 to 5.2 cm (MCA3-5.2), and 0 to 5.2 
cm (MCA0-5.2) behind the nostril; nasal cavity volumes (NCV) in cm³ from 0 to 3 cm (NCV0-
3), 3 to 5.2 cm (NCV3-5.2), and 0 to 5.2 cm (NCV0-5.2) behind the nostril. After the initial 
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 recordings at baseline, the nasal mucosa was decongested with topical xylometazoline 
(Otrivin 1 mg/ml, Novartis, Basel, Switzerland), two doses given in each nasal cavity, applied 
in a standardized manner using a hand pump. The mucosa was considered decongested after 
10 minutes 
Nasal congestion index (NCI) 
The effect of topical xylometazoline on MCA, NCV and PNIF was assessed by 
calculating the nasal congestion index (NCI) (175) for each variable using the following 
equation: NCI (post xylometazoline value-baseline value)/baseline value. A low NCI 
indicates minor mucosal congestion as opposed to a high NCI which suggests a high degree of 
reversible mucosal congestion. 
PNIF 
Peak nasal inspiratory flow was assessed with a portable PNIF meter (In-check DIAL; 
Clement Clarke International, Harlow, Essex, UK). The average of three satisfactory maximal 
nasal inspirations before and after decongestion with topical xylometazoline (Otrivin ® 1 
mg/ml) two doses in each nasal cavity was recorded with the patient in the sitting position. 
Maximum flow registration was limited to 120 l/min. Peak flows exceeding 120 l/min were 
recorded as 120 l/min.  
Skin prick test or specific IgE 
Sensitization to house dust mite, cat, dog, horse, timothy grass and birch pollens, 
mugwort and cladosporium was assessed with either specific IgE measurement (AlaTOP, 
Diagnostic Products Corporation, Los Angeles, California, USA) or skin prick tests 
(Soluprick SQ, ALK-Abello, Horsholm, Denmark). Antihistamines were discontinued 4 days 
prior to skin prick tests. Subjects with typical symptoms of hypersensitivity on exposure to 
the allergen(s) and positive tests were classified as allergic. 
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 Spirometry 
 Lung function was assessed by flow volume spirometry (Spirostar USB spirometer, 
Medikro Oy, Kuopio, Finland) before and 10 minutes after administration of 0.4 mg 
salbutamol in a spacer (Ventoline, Volumatic, GlaxoSmithKline, Middlesex, UK). The best 
FEV1 in liters and percentage of predicted (176) of 3 acceptable attempts before and after 
salbutamol was recorded, in accordance with international guidelines (177). Predicted normal 
values were based on reference values of Crapo et al (176). 
 
3.4 Statistics 
In study 1 power calculations for inclusion of patients concerning SNOT-20 were done 
prior to initialization. To obtain 80% power, we needed 100 participants in each group at a 
significance level of 0.05 (alpha) and given  a difference in SNOT-20 of 0.4 between the 
groups (162). If the difference in SNOT-20 were 0.5 the estimated power was 94%. The data 
were tested for normal distribution using normal probability plots and continuous variables 
were presented as mean ± SD. Categorical variables were presented as numbers (%). 
Differences in mean values were evaluated by independent samples t-test. The correlation 
between ACQ score and SNOT-20 and between ACQ score and nasal obstruction VAS (NO-
VAS) were assessed by linear regression. A p-value of <0.05 was considered to be 
statistically significant. 
In study 2, the data were tested for normal distribution using normal probability plots. 
The independent samples t-test was used to evaluate differences in mean values in the 
asthmatic and control groups. Analysis of variance (ANOVA) with the post hoc application of 
Bonferroni correction was used to assess the effect of allergy status in both asthma and 
control groups. A p-value of <0.05 was considered to be statistically significant. 
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 In study 3 the level of education was categorized as either basic (≤ 9 years), secondary 
(10 to 12 years), or tertiary (≥ 13 years), that has been shown to be a good surrogate for 
socioeconomic status in Norway (178, 179). Subject co-morbidity was defined as the regular 
use of medication during the last 6 months prior to recruitment for asthma and allergy, pain 
relief, ischemic heart disease and hypertension, musculoskeletal disease, thyroid disorders, 
diabetes mellitus, anxiety and depression. Disease status was categorized as cardiovascular 
disease, other disease and no disease. Smoking status was dichotomized as smoker (current or 
ever smoked) and nonsmoker, as we did not have precise information about cigarette 
consumption. NO-VAS was categorized as mild (0-30 mm), moderate (31-70 mm) and severe 
(71-100 mm) (180). PNIF was used as a continuous variable for linear regression analysis and 
as an ordinal variable for ordinal logistic regression analysis. For the latter analysis, PNIF was 
categorized into the following 3 groups: (1) high: ≥ 120 L/min, (2) medium: 90 - 119 L/min 
and (3) low: 15 - 89 L/min. Of the spirometry variables, FEV1 is the most robust, and FEV1 
(% predicted) was chosen for linear regression as that is based on height, age, sex and 
ethnicity of the subject. As there was a strong association between asthma and FEV1 (% 
predicted) (t-test, p<0.001), we fitted two separate models for PNIF as a continuous variable 
to avoid multicollinearity. The associations between PNIF and asthma and between PNIF and 
FEV1 (% predicted) were modeled with linear regression. Possible confounders such as 
allergy, other diseases, education, NO-VAS, MCA, weight, height, age, sex and smoking 
were tested. The model fit was good and assumption of normally distributed residuals was 
fulfilled. Further, we fitted ordinal logistic regression to assess possible association between 
VAS (in three categories) and having asthma. PNIF was omitted from the final model as we 
found the same ratio between having asthma and VAS score when stratified by PNIF group so 
there was no interaction between PNIF and asthma. The assumption of parallel lines was 
fulfilled and the model fit was good. The results were expressed as odds ratios (OR) with 95% 
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 confidence intervals (CI). A p-value of <0.01 was considered statistically significant to 
correct for multiple testing. 
All analyses were performed using PASW Statistics, version 18 (paper 1 and 2) and 20 
(paper 3) for Windows (SPSS Inc., Chicago, IL, USA). 
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 4 Summary of the results of the papers 
4.1 Results paper 1 
Both allergic- and non-allergic asthmatics were associated with increased sino-nasal 
symptoms, reduced sino-nasal QoL, and reduced inspiratory nasal air flow compared to 
controls 
 
4.2 Results paper 2 
We found significantly smaller MCA and NCV in asthmatics than controls and the 
cross sectional area is at its minimum at 2-3 cm from the nasal orifice in both groups. AR and 
PNIF measurements are not different in allergic and non-allergic subjects in either group. The 
effect of xylometazoline is not significantly different between the 2 groups with regard to AR, 
but there is a significant improvement in PNIF for the asthmatics when assessed by the NCI. 
 
4.3 Results paper 3 
We found that PNIF is influenced by an asthma diagnosis and FEV1 (% predicted), 
and that asthmatics are more likely to be in a higher NO-VAS category (mild 0-30 mm, 
moderate 31-70 mm and severe 71-100 mm) which is independent of PNIF group (high, 
medium and low flow). Other factors associated with PNIF are the degree of nasal obstruction 
measured both subjectively on a visual analogue scale and objectively with acoustic 
rhinometry, age and disease status. Thus in patients presenting with nasal obstruction PNIF 
recordings should be assessed in conjunction with an asthma diagnosis, spirometry and MCA. 
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 5 General discussions  
5.1 Methodological considerations 
Design 
A case-control observational design was used in this study. When all data are collected 
simultaneously, special caution has to be taken when interpreting the data and especially to 
establish any relationship between cause and effect. However, case-control studies have made 
important contributions as instruments for generating hypothesis. If several case-control 
studies point in the same direction this may have some weight in causality issues as well. 
 
Subjects 
To ensure external validity the selection of a representative sample is always 
important. In this thesis all asthmatics were recruited from the Department of Thoracic 
Medicine, St. Olavs Hospital, Trondheim University Hospital. This is a tertiary referral 
hospital for three counties of Møre and Romsdal, Sør-Trøndelag and Nord-Trøndelag with a 
total of 695,000 inhabitants and a secondary referral hospital for the population of Sør-
Trøndelag with 302,000 inhabitants. Although a tertiary hospital, all asthmatics were resident 
in Trondheim. One might argue that some of the asthmatics recruited were severely affected 
by their disease. The mean ACQ score of the asthmatics was 1.6 (SD = 1, 95% CI, 1.4-1.8) 
(181) and according to Juniper et al. (182) an ACQ score of 1.50 or greater indicate that there 
is an 88% chance that the asthma is not well-controlled. This might represent a self-selection 
bias where asthmatic patients who experienced more symptoms were most likely to respond 
to the research invitation.  
The non-asthmatics were individuals recruited from businesses near by the hospital or 
patients attending the hospital for other illnesses, which were thought not to affect the upper 
and lower airways. Those who chose to participate might have been more interested in their 
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 health than the general population. Ideally, controls should have been asked to participate 
from a random selection from a national registry (e.g. Norwegian Tax 
Administration/Folkeregisteret), but this was thought to be difficult in our small clinical 
study, due to administrative conditions. Still we regard measurements on the controls to be 
representative for the general population. 
 
Methods 
To ensure internal validity the selection of proper instruments for performing the tests 
is important. In the subjective assessment at least two biases could affect the outcome 
variables. Firstly, recall biases may influence the pattern of response and cause over- or 
underestimation of symptoms and questions of QoL. Grading of the VAS symptoms were 
during the last week, for the SNOT-20 questions during the last two weeks and for the ACQ 
questions during the last week prior to inclusion, and bias were sought minimalized due to a 
short period of recall. Secondly, response biases reflect an intentionally incorrect response, 
and could be relevant in smokers who may intentionally underestimate their smoking. In 
paper one, 9 % of asthmatics and 13 % of controls were current smokers, in paper two, 10 % 
of asthmatics and 13 % of controls were current smokers, and in paper three, 13 % of 
asthmatics and 23 % of controls were current or ever smokers. The % smokers in the 3 studies 
changed as the number of participants and the dichotomizing for current smoking versus 
current or ever smokers in these studies differed. Smoking is generally known to be 
underreported. 
Objective assessment of the nasal airway is associated with some uncertainty due to 
the nasal cycle. AR and PNIF only provide snapshots of nasal geometry and flow and say 
nothing about dynamics like the resistance. Also, PNIF gives a global characterization of the 
nasal air flow, but does not give any information about the separate nasal passages or nasal 
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 airflow under resting conditions. Other modalities like rhinomanometry, CFD and PIV could 
have added extra knowledge to this thesis. CFD and PIV would have been very expensive and 
time consuming for the nearly 200 patients included in this thesis. Multiple testing by 
repeated recordings over several hours could allow a more comprehensive assessment of the 
mucosal changes but would be very time consuming in the clinical setting.  
 Decongestion with topical xylometazoline was performed in a standardized 
manner with the administration of two doses of xylometazoline in each nasal cavity (169). Its 
pharmacological effects on the nose have been examined in previous studies (133, 183). 
Several factors could affect and decrease the decongestive response, such as inflammatory 
conditions, differences in sensitivity of the mucosa, differences in delivery of the agent due to 
anatomical conditions, and stimuli of other triggers, e.g. medications, rhinitis medicamentosa 
etc. (184). 
 To exclude the possible confounding of seasonal allergy none of the study participants 
were included during the pollen season. Antihistamines used for perennial allergy were 
discontinued 4 days prior to skin prick tests. 
Spirometry was performed under standardized conditions (177), and individual 
spirograms were acceptable if they were free from artefacts such as cough during the first 
second of exhalation, glottis closure that influenced the measurement, early termination or 
cut-off, effort that was not maximal throughout, leak and an obstructed mouthpiece. Further 
they had to show satisfactory exhalation (duration of ≥ 6 seconds) and an extrapolated volume 
< 5% of forced vital capacity or 0.15 liter, whichever is greater. 
 
Statistics 
 The number of participants included in study 1 was based on power calculations. For 
the outcome variables in study 2 and 3 we did not perform power calculations.  
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 Although correlation coefficients are frequently applied to estimate the strength of an 
association between variables (185), it cannot replace regression which provide much more 
detailed information (186), and thus multiple regression analysis was used in study 3 to assess 
the association between a diagnosis of asthma and of lung function on PNIF when adjusted 
for possible confounders.  
 
5.2 Evaluation of results 
The main finding of this thesis is that asthmatics have a smaller nasal airway than 
controls measured by cross-sectional area and volume, and that the sensation of nasal 
obstruction in asthmatics is different from controls despite being in the same PNIF group. We 
also found increased nasal symptoms and decreased sino-nasal quality of life in asthmatics 
compared to controls. Moreover, the nasal airflow measured by PNIF is significantly lower in 
asthmatics than controls, and we found that asthma, FEV1 (% pred), degree of nasal 
obstruction measured both subjectively on a VAS and objectively with AR, age and disease 
status are other factors which influence nasal airflow. Further, in all three studies, we found 
no difference in major outcome variables between asthmatics and controls with and without 
allergy.  
 
The smaller nasal airway of asthmatics 
What I consider the most important contributions of this thesis to clinical and 
scientific medicine are the documentation of a geometrically smaller nasal airway in 
asthmatics than in controls. The smaller size of the nasal airway in terms of nasal cavity 
volume and  minimal cross sectional areas is previously studied by two research groups (24, 
187) where our findings are in accordance with that of Hellgren et al.(24).  
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 One critical issue that needs to be addressed here is to what extent the smaller airways 
is something that asthmatics are born with, or to what extent it is acquired. To my knowledge, 
the data necessary to answer this question does not currently exist. However, it has been 
shown by X-ray that asthmatic children have a reduced epipharyngeal airway compared to 
controls (111). Another issue is whether the reduction in nasal airway geometry in asthmatics 
compared to non-asthmatics is caused by the reduced size of the bony and cartilaginous 
boundaries of the nose or is due to mucosal abnormalities. There are conflicting results 
concerning structural changes such as basal membrane thickening in the nasal mucosa of 
patients with asthma (188, 189). In the former study they found no difference, whereas in the 
latter they found that the thickness of the basal membrane in the corticosteroid-dependent and 
untreated asthmatics was significantly increased compared with that in control subjects. 
Further, nasal mucosal inflammation with eosinophilic infiltration has been reported in 
asthmatic subjects without rhinitis (190). Dhong et al (191) found thickening of the basement 
membrane, goblet cell hyperplasia and eosinophil infiltration to be more prominent when 
examining the mucosa of the sinuses in asthmatics compared to non-asthmatics.  
Another speculation is whether the asthmatics turn into oral breathers at an earlier 
stage than non-asthmatics due to the smaller nasal airway geometry. Both the smaller airways 
and the increased experience of nasal blockage may increase the tendency of mouth breathing 
that in turn deteriorates the physiological condition of the air that enters the lungs.  
Given that asthmatics, due to nasal anatomy or experience of a blocked nose, prematurely turn 
to oral breathing, the flow in the nasal airways will consequently decrease. There are 
examples illustrating that the short cut or immobilization of organs lead to changes such as 
atrophy and functional loss. This is the case in patients who have undergone a total 
laryngectomy where the nose is excluded from the respiration and thus changes of the 
physiological functions occur. It is found that the dimensions of the nasal cavity measured by 
61 
 acoustic rhinometry are found to be significantly and permanently reduced 1 year after total 
laryngectomy, attributable to the fact that they no longer use their noses (192). 
 
The different perceptions of nasal patency 
The second most important finding of this thesis is the documentation of different 
perceptions of nasal patency between asthmatics and controls. The opportunity to measure 
nasal patency objectively, and to get a true correlate to the patient’s subjective apprehension 
of nasal obstruction is still one of the core challenges in rhinology. We found that the 
experience of nasal obstruction was 19-fold greater in asthmatics compared to non-asthmatics 
despite being in the same PNIF group. One can speculate whether an increased number of 
sensory sodium channels and sensory- and secretomotor nerve fibers in the nasal mucosa, that 
has been reported in allergic and non-allergic rhinitis (193, 194), may account for the 
increased perception of nasal obstruction. The level of perceived breathing difficulty has been 
reported to be more important than the applied nasal load for the increased propensity of 
asthmatics to switch to oronasal breathing, compared with non-asthmatic subjects (86).  
Premature switching to oronasal breathing results in inadequate conditioning and filtering of 
the inspired air, with drying and cooling of the lower airways, subsequent release of 
inflammatory cell mediators and development of an asthmatic response (195) and asthma 
chronicity.  
A patient’s perception of nasal obstruction may depend on factors beyond the physical 
caliber of the nose. Patients with objectively measured, longstanding nasal obstruction (e.g., 
cartilaginous or bony obstruction) may become desensitized to the severity of obstruction 
over time and rate themselves as having no problem with nasal obstruction, in contrast to 
patients with no objective nasal obstructions who complains about blocked noses. Studies 
have shown that the inhalation of menthol, certain volatile oils, camphor, eucalyptus or 
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 vanilla causes a perceived increase in nasal patency without a corresponding reduction in 
nasal airway resistance (108, 196). Conversely, it has been shown that local anesthesia of the 
nasal vestibule produced sensations of nasal obstruction without change in the nasal airway 
resistance (197). Perhaps greater focus upon nasal breathing as a mean for patients with 
obstructive lung disease to better master their lower airway disease would be beneficial. It has 
been shown in randomized trials that asthma patients may benefit from a controlled breathing 
pattern as in yoga (198, 199) although a recent review showed no evidence for effects of yoga 
compared with sham yoga or breathing exercises (200).  
The increased nasal symptoms and decreased sino-nasal quality of life in asthmatics 
compared to controls is in line with data reported by Hens and coworkers (23). They found 
that allergic asthmatics, non-allergic asthmatics and patients with chronic obstructive 
pulmonary disorder reported more nasal symptoms than their respective control subjects, had 
a higher SNOT-22 score and presented more mucosal abnormalities in the nose. 
 
Allergy and the unified airway 
Both allergic and non-allergic asthmatics were associated with increased sinonasal 
symptoms, reduced sino-nasal QoL, reduced inspiratory nasal air flow, and significantly 
smaller minimum cross sectional area and nasal cavity volume compared to controls. Allergy 
was not a significant confounder when we investigated the effect of a diagnosis of asthma and 
of lung function on PNIF. It is previously reported that both allergic and non-allergic asthma 
patients had more nasal symptoms and mucosal abnormalities in the nose and had elevated 
levels of inflammatory markers in nasal secretions (23). Further, the COPSAC study (201) 
examined a birth cohort of children born to mothers with a history of asthma, and they found 
that non-allergic rhinitis was twice as common as allergic rhinitis, which is different from 
studies of adults where the proportion of subjects with non-allergic rhinitis is one third to one 
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 fourth of the rhinitis population (202, 203). Thus nasal inflammation has to be taken in to 
account in the diagnostic and therapeutic approach of all asthmatic patients, beyond the scope 
of allergic inflammation (23, 204). 
 
PNIF and pulmonary function 
We also found that PNIF is influenced by an asthma diagnosis and FEV1 (% 
predicted). Other factors associated with PNIF are the degree of nasal obstruction measured 
both subjectively on a visual analogue scale, objectively with acoustic rhinometry, and age as 
well as disease status. Previous studies show a positive correlation between upper airway 
patency measured by PNIF and lower airway function measured by PEF in adults (205) and in 
children and adolescents (206). Moreover, an increase in PNIF with a concomitant increase in 
FEV1 (% predicted) has been reported in allergic rhinitis after sauna treatment (207).  
 Thus in patients presenting with nasal obstruction, PNIF and AR should be performed 
in conjunction with considerations about concomitant asthma and spirometry.  
 
5.3 Limitations 
One limitation of this thesis is that the PNIF meter we used has a scale from 15-120 
L/min. We should ideally have used the PNIF meter with a scale from 30-370 L/min which 
gives the full range of nasal inspiratory flow. Nevertheless, the manufacturer, Clement Clarke 
International confirms that both instruments are calibrated identically, with a performance 
accuracy of ± 10 % or 10 l/min (whichever is greater) and repeatability of ± 5 l/min. Thus the 
results in the range 15-120 l/min will be similar for either instrument and the In-Check Dial is 
used in other studies evaluating nasal obstruction (175, 180, 208-210). A normal value of 
greater than 120 L/min is commonly used (211) and PNIF values above 120 L/min are only of 
minor clinical interest because such high peak flows generally exclude nasal obstruction (180, 
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 212). PNIF in excess of 120 L/min was recorded as 120+ L/min, and in paper 3, for the 
purpose of statistical analysis, set to 120 L/min. Regarding the individuals with PNIF> 120 
L/min (5 asthmatics and 21 controls) in paper 3, we performed sensitivity analysis where 
these individuals were omitted which confirmed our original findings. Also, the purpose of 
the study in paper 3 was not to give normative data for PNIF in asthmatics, but to show which 
factors influence the measurement and interpretation of PNIF in patients with asthma. I 
believe that we have been able to do that despite the limitations of the scale of the PNIF 
meter.  
Another limitation is that SNOT-20 lacks questions about nasal obstruction and loss of 
smell, which are important aspects in the evaluation of sino-nasal QoL. Further, spirometry 
and PNIF are highly effort dependent methods. Reliability depends on cooperation, 
instructions, and standardized techniques, and close attention was paid to these elements for 
the spirometry, AR and PNIF recordings. 
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 6 Conclusions 
Asthmatics need to be met with the understanding of the concept of the unified airway, 
both in the practice of pulmonary- and otorhinolaryngological medicine. The ability to 
translate the principles of the unified airway into successful strategies for diagnosis and 
treatment can lead to improved patient outcomes and quality of life in asthmatics. 
In analogy with the proposed specific aims, our main conclusions are as follows: 
-Asthmatics have a smaller nasal airway measured by MCA and NCV compared to controls. 
-Asthmatics have an increased sensation of nasal obstruction compared to controls. 
-Asthmatics have increased sino-nasal symptoms and reduced sino-nasal QoL compared to 
controls 
-Asthmatics have reduced PNIF compared to controls, but special care has to be taken when 
interpreting PNIF values in patients with asthma or reduced FEV1 (% pred). 
-The above findings are irrespective of allergy in both asthmatics and controls. 
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 7 Future studies 
The goal of future studies concerning The Unified Airway would be to answer the 
essential question: Should the potential of nasal- and sinus disease in asthmatics be 
investigated and treated more extensively, both medically and surgically with the defined goal 
of promoting nasal breathing, and does this have any influence on the long-term management 
of their asthma?  
Several investigations have to be carried out to answer this question, and they should include: 
-Medical interventions on the nose and how this affects the lungs. 
-Surgical interventions on the nose and how this affects the lungs. 
-The follow up of a birth cohort with subjective and objective methods of the nose and relate 
to the development of asthma. Surgical interventions such as adenoidectomy and 
tonsillectomy in childhood and the impact on asthma could also be addressed.  
-The results of paper 2 indicate a need for nasal biopsy studies in asthmatics to further 
understand the structural changes of the nasal mucosa in asthmatic patients compared to the 
nasal mucosa of healthy individuals.  
-PNIF is a very commonly used measurement tool for nasal airflow, and there is a need to 
perform similar studies of PNIF and pulmonary function of patients with other pulmonary 
diseases than asthma.  
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 9 Appendix 
Laminar flow occurs when a fluid, i.e. a liquid or gas, flows in layers, with no 
disruption between the layers. The motion of the fluid particles is very orderly with no 
particle exchange between the layers. Turbulent flow is characterized by a random and 
disordered pattern of flow where the fluid particles exchange momentum between regions of 
different velocities creating eddies of various scales. Compared to laminar flow over a flat 
surface, turbulent flow creates a larger drag, i.e. a larger force on the surface dragging in the 
flow direction.    
Flow dynamics can be characterized by the Reynolds number, which expresses the 
ratio of inertial and viscous forces. Laminar flow occurs at low Reynolds numbers whereas 
turbulent flow occurs at high Reynolds numbers. For flow in a pipe or channel, the Reynolds 
number, Re, is defined by Re = ρVd/µ where ρ = fluid density, V = mean fluid velocity, d = 
hydraulic diameter of the conduit (4x cross sectional area/wetted perimeter), µ = dynamic 
fluid viscosity. For a filled circular pipe, d is the pipe diameter.  
The physical principles of fluid flow are based on well-known laws of physics, namely 
the conservation of mass, Newton’s second law and the first law of thermodynamics. 
Poiseuille’s law states that the volumetric flow rate of a fluid flowing in a circular pipe is 
directly proportional to the difference in pressure at inlet and outlet times the radius of the 
pipe raised to the fourth power. The volumetric flow rate is inversely proportional to the 
length of the pipe. ΔP = 8µLQ/(πr4), therefore Q = πr4 ΔP/(8µL) 
Where ΔP = the pressure loss (P inlet – P outlet), µ = the dynamic viscosity of the fluid, L = 
the length of the pipe, Q = the volumetric flow rate, r = is the radius of the pipe, π = 
mathematical constant ≈ 3.14 
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 Bernoulli’s principle states that the total pressure in an incompressible inviscid flow is 
constant along a streamline. The total pressure, which equals the sum of the static pressure 
and the dynamic pressure, remains constant in the whole flow field, if the incompressible 
inviscid flow is irrotational.  
p0 = p + q  
p0 = total pressure, p = static pressure, q = dynamic pressure 
The dynamic pressure can be expressed as 1/2ρV2 where ρ = density and V = modulus of the 
fluid velocity, hence p0 = p + 1/2ρV
2 
An increase in the velocity of a fluid occurs simultaneously with a decrease in the static 
pressure and vice versa.  
The Venturi effect is the reduction in static fluid pressure that results when a fluid is 
accelerated through a constricted section of a pipe, assuming the flow to be incompressible 
and inviscid. In the nose, the Venturi effect can be applied in the nasal valve region where the 
velocity of the inspired air increases, with a resulting drop in static pressure and subsequently 
inward movement of the compliant lateral nasal wall.  
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Navn: Diagnose: 
 
Alder: 
 
 
VAS-skjema for nese-bihule-symptomer 
 
 
 
 
 
 
 
 
Høyde: 
 
Vekt:          BMI:            Allergi:       Astma:       Yrke: 
 
Antall sigaretter om dagen: I hvor mange år: 
 
 
 
 
 
 
 
Tett nese 
 
 
Helt 
åpen 
 Helt 
tett 
Munnpusting 
 
 
Aldri  Alltid 
Snorking 
 
 
Aldri  Alltid 
Pustepauser under 
søvn 
 
Aldri  Alltid 
Renning fra nesen 
 
 
Aldri  Alltid 
Hodepine 
 
 
Aldri  Alltid 
Smerter i 
tenner/midtannsikt 
 
Aldri  Alltid 
Bihulebetennelse 
 
 
Aldri  Alltid 
Hoste 
 
 
Aldri  Alltid 
Nysing 
 
 
Aldri  Alltid 
Nedsatt 
allmenntilstand 
 
Aldri  Alltid 
Nedsatt luktesans Aldri  Alltid 
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       Kjærgård/Steinsvåg -06 
 
 
SINO-NASAL OUTCOME TEST 
 
 
 
Nedenfor finner du en liste over symptomer og sosiale/følelsesmessige konsekvenser av din 
neselidelse. Vi vil gjerne vite mer om disse problemene, og vil være takknemlig hvis du vil 
besvare nedenstående spørsmål etter beste evne. Det er ikke noen riktige eller feile svar, og 
bare du kan gi oss den rette informasjonen. Vær vennlig å gradere dine problemer med 
utgangspunkt i situasjonen de siste to uker. Takk for at du vil delta. 
 
 
 
A. 
Med utgangspunkt i hvor 
uttalt problemet er når det 
oppstår og hvor ofte det 
opptrer, bes du angi hvor 
”ille” det er ved at markere 
med sirkel det tallet som best 
svarer til det du føler, ut fra 
denne skala →→→→→→→ 
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     V
ik
tig
ste p
u
n
k
ter (5
) 
1.   behov for å pusse nese           ⁬ 
2.   nysing           ⁬ 
3.   rennende nese           ⁬ 
4.   hoste           ⁬ 
5.   renning bak i svelget           ⁬ 
6.   tykt sekret fra nesen           ⁬ 
7.   tetthet i ørene           ⁬ 
8.   svimmelhet           ⁬ 
9.   øresmerter           ⁬ 
10. smerter/trykk i ansiktet           ⁬ 
11. vanskelig å  falle i søvn           ⁬ 
12. våkner om natten           ⁬ 
13. mangel av god nattesøvn           ⁬ 
14. trøtt når du våkner           ⁬ 
15. kraftesløshet            ⁬ 
16. nedsatt produktivitet           ⁬ 
17. nedsatt konsentrasjon           ⁬ 
18. frustrert/rastløs/irritabel           ⁬ 
19. trist           ⁬ 
20. flau             ⁬ 
                                                                                                                                                    ↑ 
                                                                                                                                                    ↑   
B.                                                                                                                                                 ↑ 
Vær vennlig å markere de viktigste punktene som påvirker din helsetilstand (maksimum 5 
punkter)  
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NESE-BIHULE RELATERT LIVSKVALITET HOS ASTMATIKERE 
 
Generelle helseopplysninger 
 
 
 
Dato for utfylling: _____________            Pasient nr. ___________________ 
 
1:  Alder _______ år   2:  Høyde ______ cm  3:  Vekt:  ________ kg    
 
4:  Kjønn    □  Kvinne  □  Mann 
5:  Har du pollenallergi?      □ Ja   □ Nei 
6:  Har du dyreallergi?         □  Ja  □  Nei 
7:  Har du middallergi?        □  Ja  □   Nei 
8:  Bruker du medisiner?      □ Ja  □   Nei    Hvis ja, hvilke:_________________________ 
                                                                                                   _________________________ 
 
 
9: Har  du andre  
   sykdommer?                       □ Ja  □   Nei    Hvis ja, hvilke:_________________________ 
                                                                                                   _________________________ 
 
 
10:  Røyker du?                      □ Ja  □ Nei    Hvis ja, hvor mange pr dag      □□ sigaretter 
                                                                          Hvor lenge har du røkt?            □□ år 
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Critical parameters of the nasal airway can be quantified objectively with acoustic rhi-
(AR) and peak nasal inspiratory flow (PNIF).
e: We aimed to investigate nasal airway patency in asthmatics compared to non-
c controls. Nasal volume, cross sectional area and flow were measured using acoustic
ry (AR) and peak nasal inspiratory flow (PNIF) in 87 asthmatics and 93 non-asthmatic
before and after decongestion with xylometazoline. Nasal congestion index (NCI) was
d, and allergy status was assessed by skin prick test or specific IgE.
We found significantly smaller minimum cross sectional area and nasal cavity volume
atics than controls, and the cross sectional area is at its minimum at 2e3 cm from the
fice in both groups. AR and PNIF measurements are not different in allergic and non
ubjects in either group. The effect of xylometazoline is not significantly different be-
e 2 groups with regard to AR, but there is a significant improvement in PNIF for the
cs when assessed by the NCI.
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troduction
e Unified Airways hypothesis suggests an involvement of
e upper airways in asthma [1e3]. Rhinitis typically pre-
des the development of asthma and can contribute to
satisfactory asthma control. Nasal symptoms, airflow,
d markers of inflammation directly correlate with lower
rway involvement [4]. In both rhinitis and asthma, an
flammatory cell infiltrate with subepithelial oedema is
esent in the mucosa [5]. Unlike the lower airway, the
sal mucosa contains venous sinusoids that undergo peri-
ic congestion and decongestion (the nasal cycle) that are
portant for regulation of airflow, humidification and
rming of the inspired air. Nasal obstruction may be
dicative of structural deformities, infections and inflam-
atory conditions in the nose, and is frequently reported
asthmatics [6]. Their lack of nasal patency may also be
e to factors such as mucosal congestion and changed
rception of flow.
Critical parameters of the nasal airway can be quantified
jectively with acoustic rhinometry (AR) and peak nasal
spiratory flow (PNIF) [7,8]. While the former measures
ternal nasal volume and minimum cross-sectional areas,
e latter measures the maximum nasal inspiratory flow
ring forced inspiration. The Nasal Congestion Index (NCI)
s been suggested as a useful instrument for the evalua-
n of nasal obstruction by quantifying the effect of topical
congestants applied on the nasal mucosa [9]. There are
w studies that have used these tools to investigate the
lative contribution of subepithelial oedema and conges-
n of the venous sinusoids in asthmatics. Hellgren et al.
0] demonstrated increased nasal mucosal swelling in
thmatics compared to healthy controls.
In this study, we measured nasal volume, cross sectional
ea and flow using AR and PNIF, and assessed the effect of
lometazoline using the NCI in order to further elucidate
e role of oedema and congestion in the nasal mucosa of
thmatics.
ethods
bjects
e study consisted of 87 patients with asthma, and they
re recruited from the out-patients’ clinic at the
partment of Lung Medicine, St Olavs Hospital, University
spital of Trondheim. The asthma diagnosis was based on
e presence of typical asthma symptoms, with either 12%
d 200 ml improvement of forced expiratory volume in
e first second (FEV1) from baseline after inhalation of
lbutamol or positive methacholine bronchial provocation
st (PD20 FEV1  1600 mg) and in accordance with the
itish Thoracic Society criteria [11].
Ninety-t
recruited f
Otolaryngo
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randomly i
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16significantly smaller nasal airway when assessed
avity volume in asthmatics than controls, and
s irrespective of allergy status.
e non-asthmatic controls were mostly
the out-patients’ clinic of Department of
, Head and Neck Surgery, St Olavs Hospital,
pital of Trondheim, among patients with dis-
cting the upper airways (e.g. external otitis,
es in the ENT area). Some controls were also
ed from nearby businesses with all types of
from manual labour to skilled work. The sam-
tus, questionnaires and additional recordings
a database that has previously been described
riteria were the presence of acute and chronic
nd nasal polyposis on oto-rhino-laryngological
nd in accordance to the EPOS 2012 criteria
y, previous nasal surgery, systemic diseasewith
ction of the nose, such as Wegener’s gran-
stic fibrosis, primary ciliary dyskinesia, Karta-
e and sarcoidosis, and a history of cancer. For
alyzed 85 patients with asthma and 93 non-
trols. The missing values were discarded
W.M. Thorstensen et al.s approved by the Regional Committee for
rch Ethics, and conducted according to the
ation.Written informed consentwas obtained.
ho technique which was used to measure the
and minimal cross sectional areas. Nasal
es are calculated from contiguous cross-
s.
ements were made with an impulse acoustic
hinoMetrics SRE2100, Rhinoscan version 2.5,
Interacoustics, Minneapolis, MN) by two
tors throughout the study. The probe was
the subject sitting upright and opposite to
r. An appropriate anatomic nose adaptor and
tween the nose adaptor and the nostril were
surements were made during a breath hold.
were performed according to published pro-
riefly, three satisfactory recordings were
ch nasal cavity. The values for each nasal
eraged. Due to the variations represented by
, the sum of the two averages was divided by
minimal cross sectional area (MCA, cm2) and
lume (NCV, cm3). The rhinometer was pro-
lculate the MCA0e3 and MCA3e5.2, and NCV0e3
defined as MCA and NCV at 0e3 cm and
pectively from the nasal orifice. MCA0e5.2 is
cross sectional area at 0e5.2 cm from the
CV0e5.2 is the sum of NCV0e3 and NCV3e5.2.
l inspection of the rhinometric curves, the
as reprogrammed to calculate MCA0e2 and102 
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(SD) or 95% confidence interval (95% CI). The in-
samples t test was used to evaluate differences
alues in the asthmatic and control groups. Anal-
iance (ANOVA) with the post hoc application of
correction was used to assess the effect of al-
s in both asthma and control groups. A P-value of
considered to be statistically significant.
Na 1517CA2e4, and NCV0e2 and NCV2e4, defined as 0e2 and
4 cm, respectively from the nasal orifice. MCA0e4 is the
inimum cross sectional area at 0e4 cm from the nasal
ifice. NCV0e4 is the sum of NCV0e2 and NCV2e4.
IF
ak nasal inspiratory flow was assessed with a portable
IF meter (In-check DIAL; Clement Clarke International,
rlow, Essex, UK). The average of three satisfactory
aximal nasal inspirations with the patient in the sitting
sition was recorded.
Maximum flow registration was limited to 120 l/min. Peak
ws exceeding 120 l/min were recorded as 120 l/min.
asal decongestion
ter baseline recordings of AR and PNIF, the nasal mucosa
as decongested with two sprays of topical xylometazoline
trivinVR 1 mg/ml, Novartis, Basel, Switzerland) applied in
standardized manner with a hand pump to each nasal
vity. Recordings of AR and PNIF were repeated after
min.
CI
e effect of topical xylometazoline on MCA, NCV and PNIF
as assessed by calculating the Nasal Congestion Index [9]
r each variable using the following equation: NCIZ (post
lometazoline value  baseline value)/baseline value.
A low NCI indicates minor mucosal congestion as
posed to a high NCI which suggests a high degree of
versible mucosal congestion.
llergy
nsitization to house dust mite, cat, dog, horse, timothy
ass and birch pollens, mugwort and cladosporium was
sessed with either specific IgE measurement (AlaTOP,
agnostic Products Corporation, Los Angeles, California,
A) or skin prick tests (Soluprick SQ, ALK-Abello, Hor-
olm, Denmark). Antihistamines were discontinued 4 days
ior to skin prick tests. Subjects with typical symptoms of
persensitivity on exposure to the allergen(s) and positive
sts were classified as allergic.
atistics
e data were tested for normal distribution using normal
deviation
dependent
in mean v
ysis of var
Bonferroni
lergy statu
<0.05 was
sal characteristics in asthmaticsobability plots and presented as mean, standard
Table 1 Patient demographics.
Asthmatics,
N Z 87
Controls,
N Z 93
Mean age, years (range) 43.7 (19e64) 44.0 (20e65)
Mean BMI, kg/m2 (SD) 26.8 (5.0) 25.2 (3.3)
Gender, Male, n (%) 36 (41) 41 (44)
Allergy, n (%) 52 (60) 20 (22)
Smoking, n (%) 9 (10) 12 (13)
Figure 1 MC
asthmatic patie
presented as m
cross sectional
behind the nas
orifice.A0e3 (A), MCA0e5.2 (B) and NCV0e3 (C) in the
nts (white bars) and controls (grey bars). Values
ean, 95% CI. Abbreviations: MCA Z minimum
area; NCVZ nasal cavity volume; 0e3Z 0e3 cm
al orifice; 0e5.2 Z 0e5.2 cm behind the nasal
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15All statistical analyses were performed using PASW Sta-
tics, version 18 for Windows (SPSS Inc., Chicago, IL, USA).
sults
e demographic data are presented in Table 1. The mean
5% CI) baseline FEV1 was significantly lower in asthma pa-
nts than controls [2.79 (2.61e2.97) vs 3.46 (3.26e3.65) l,
< 0.001].
inometry measurements
ta on rhinometric variables at baseline and after topical
lometazoline, calculated as the NCI, are presented in
ble 2.
MCA0e3, MCA0e5.2 and NCV0e3 were significantly lower in
thmatics than in controls (Fig. 1). In the asthma group the
A for the whole nasal airway (MCA0e5.2) was located in
e anterior region (MCA0e3) in 95% and more posteriorly
CA3e5.2) in 5% of subjects. In the control group the
A0e5.2 was located in the anterior region (MCA0e3) in 98%
d more posteriorly (MCA3e5.2) in 2% of the subjects.
A0e2, MCA2e4, MCA0e4 and NCV0e2 were significantly
wer in asthmatics than in controls (data not shown). The
west value of the MCA was located at 2e4 cm from the
sal orifice in 59 and 61% of asthmatics and controls,
spectively.
NCI was not significantly different between the groups.
spiratory flow
e mean (95% CI) PNIF was significantly lower in the
thma group compared to the control group [84 (78e89) vs
2 (98e106) l/min, P < 0.001].
The effect of xylometazoline was significantly greater in
thmatics than in controls (Table 2).
lergy
variables and PNIF were not significantly different in
Discussio
This study
assessed by
smaller in
sectional a
orifice in b
surements
groups, bu
PNIF in the
significantl
either grou
MCA and
by two oth
0e4 cm an
Hellgren et
area at 4 cm
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Wa˚linder e
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measured
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The loca
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there was
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18thmatics and controls when analyzed by allergy status
ig. 2).
enced by dec
mation with e
able 2 Acoustic rhinometry and peak nasal inspiratory flow recordings at bas
easurement level Acoustic rhinometry Nasa
Asthmatics (N Z 87) Controls (N Z 93) P Asth
CA0e3 0.47 (0.12) 0.52 (0.12) 0.01 0.12
CA3e5.2 0.89 (0.35) 0.92 (0.27) 0.57 0.65
CA0e5.2 0.47 (0.12) 0.52 (0.12) <0.01 0.13
CV0e3 2.35 (0.46) 2.53 (0.42) <0.01 0.09
CV3e5.2 2.95 (1.16) 2.97 (0.88) 0.89 0.43
CV0e5.2 5.30 (1.45) 5.50 (1.20) 0.32 0.25
NIF 84 (24.4) 102 (18.8) <0.001 0.14
ata presented as mean (SD). Abbreviations: MCAZ minimum cross sectional area; NC
ndex; SDZ standard deviation; 0e3Z 0e3 cm behind the nasal orifice; 3e5.2Z 3e5.
ehind the nasal orifice; PNIF Z peak nasal inspiratory flow.monstrates that the nasal airway, when
ss sectional area and volume, is significantly
hmatics than controls, and that the cross
is at its minimum at 2e3 cm from the nasal
groups. The NCI with regard to AR mea-
ot significantly different between the two
ere is a significant improvement in NCI for
hmatics. AR and PNIF measurements are not
fferent in allergic and non allergic subjects in
V in asthmatics have been studied previously
roups [10,14]. Our finding of a lower MCA at
CV at 0e3 cm is in accordance with that of
They found a decrease in the cross-sectional
d in the volume between 3.3 and 4 cm in the
compared with healthy controls. In contrast,
l. did not find any significant difference in
ss sectional area and intranasal volume
ween 0 and 5.2 cm in 41 asthmatics and
ls.
n of the MCA in both asthmatics and controls
rrespond with the location of the internal
e latter consists of 4 distinct compartments
istors: two structural e the cartilaginous
the nasal vestibule and the bony entrance to
nd two mucovascular compartments e the
ate and the septal erectile body, both char-
umerous venous sinusoids [15]. The magni-
is determined by the shape and dimensions
tomicalephysiological narrowings and by
y [16]. In the present study, it is unlikely that
asal patency in asthmatics is due to conges-
nous sinusoids. The decongestive effect of
is achieved by vasoconstriction of the nasal
ds via stimulation of a-2 receptors [17], and
ignificant difference in the NCI for MCA and
the two groups. Thus, the most likely expla-
differences in nasal patency is the presence
atory cell substrate, subepithelial oedema
sue in those with asthma which is not influ-
W.M. Thorstensen et al.ongestive measures. Nasal mucosal inflam-
osinophilic infiltration has been reported in
eline and nasal congestion index.
l congestion index
matics (N Z 85) Controls (N Z 93) P
(0.18) 0.09 (0.17) 0.17
(0.47) 0.67 (0.43) 0.77
(0.19) 0.09 (0.17) 0.10
(0.10) 0.09 (0.10) 0.74
(0.47) 0.43 (0.34) 0.95
(0.24) 0.26 (0.19) 0.65
(0.20) 0.06 (0.11) <0.01
VZ nasal cavity volume; NCIZ nasal congestion
2 cm behind the nasal orifice; 0e5.2Z 0e5.2 cm
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cting results concerning structural changes such as basal
embrane thickening in the nasal mucosa of patients with
thma [19,20]. Other structural factors that may represent
power. A
airway wi
[21], illus
consequen
sal characteristics in asthmaticsdifference are nasal polyps, CRS, previous nasal surgery
d chronic immunological/inflammatory conditions, but
bjects with these abnormalities were excluded from the
esent study.
Nasal airway patency depends on the geometry of the
rway, airflow and resistance. According to Poiseuille’s
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gure 2 MCA0e3 (A), MCA0e5.2 (B) and NCV0e3 (C) in the
lergic asthmatic patients, non-allergic asthmatic patients,
lergic controls and non-allergic controls. Values presented as
ean, 95% CI. Abbreviations: MCA Z minimum cross sectional
ea; NCV Z nasal cavity volume; 0e3 Z 0e3 cm behind the
sal orifice; 0e5.2 Z 0e5.2 cm behind the nasal orifice.imal decrease in the radius of the nasal
us result in a significant reduction in flow
ed in this study by a reduced MCA and a
reduced PNIF in the asthma group. In con-
, velocity increases and a relatively negative
nerated [21]. These phenomena are seen in
asal valve which represents the flow-limiting
ottle-neck area of the nasal cavity. Although
hanges in NCI MCA in the asthmatic and
s are equal the MCA in the asthma group is
d this may explain the persistent difference
decongestion. In addition to structural and
cteristics, other factors may control nasal
duction in forced inspiration may give a
lation of the sensors for nasal airflow. When
effort is sub maximal or intrapulmonary dy-
nce is increased, reduced PNIF can give a
pression of nasal obstruction. It has also been
t asthmatics generally may just have a
ective perception of nasal obstruction that
heir oronasal breathing [22].
is a dynamic process, with turbulent and
ccurring simultaneously in different parts of
age. AR is static in nature and thus has limi-
egard to detecting dynamic changes. On the
NIF is effort dependent, but the non-rigidity
asi may induce dynamic collapse in the
t of the external nose. Despite a maximum
PNIF recordings to 120 l/min, we demon-
significant differences between asthmatics
In addition, PNIF values above 120 l/min are
clinical interest because such high peak flows
ude nasal obstruction [23,24].
hat both allergic and non-allergic asthmatics
ntly smaller MCA0e5.2 and NCV0e3 compared
ctive controls. Other studies have reported
rgic and non-allergic asthma patients had
mptoms and mucosal abnormalities in the
elevated levels of inflammatory markers in
ns, together with a significant impairment of
e and reduced inspiratory nasal airflow
non-asthmatics [4,6]. This highlights the
a thorough oto-rhino-laryngological exami-
aluation in all asthma patients, beyond the
gy.
ns in nasal cavity geometry and airflow may
ung function, the results of the present
indicate a need for nasal biopsy studies in
further understand nasal obstruction in these
so indicates a need for considering medical
terventions to open the nose for the benefit
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The determining factors of peak nasal inspiratory flow and 
perception of nasal airflow in asthmatics*
Abstract 
Background: The effect of pulmonary pathology on peak nasal inspiratory flow (PNIF) remains largely unknown. We investigated 
an association between a diagnosis of asthma and of lung function on PNIF when adjusted for possible confounders. Further, we 
investigated the perception of nasal obstruction in asthmatics compared to healthy controls when adjusted for PNIF.
Methodology: Eighty-seven asthmatics and 92 non-asthmatic controls underwent PNIF (categorized into groups of high, 
medium and low), acoustic rhinometry (AR) and spirometry, and we assessed symptoms of nasal obstruction on visual analogue 
scales (VAS) in three categories.
Results: PNIF was significantly associated with asthma and forced expiratory volume in the first second (FEV1) (% predicted). 
Other factors associated with PNIF were the degree of nasal obstruction measured both subjectively on a VAS and objectively 
with AR, age and disease status. Asthma patients were 19 times more likely to be in a higher VAS category compared to non-asth-
matic controls independent of PNIF group.
Conclusion: Special care has to be taken when interpreting PNIF values in patients with asthma or reduced FEV1 (% predicted). 
The sensation of nasal obstruction in asthmatics is different from controls despite being in the same PNIF group.
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Introduction
A large body of evidence supports the concept of a unified 
airway in which signs of disease in one part of the respiratory 
tract should be considered as a disease of the whole. This 
concept is sometimes expressed as ‘‘one airway, one disease” (1-3).  
Clinical studies show that bronchial provocation with grass pol-
len extract can induce nasal inflammation (4) and nasal allergen 
challenge in patients with allergic rhinitis can lead to increased 
airway responsiveness (5).
The incidence of asthma is increasing, and the concomitant 
presence of rhinitis and chronic rhinosinusitis with asthma 
is frequently seen (6). Assessment of the degree of sino-nasal 
dysfunction in asthmatic patients has significant clinical impact 
since it is important to diagnose and treat pathology in the up-
per airways to relieve symptoms from the lower airways (7,8). It is 
also known that rhinitis can be the first sign of a lower respira-
tory tract disorder and the degree of upper airway disease can 
to some extent determine the severity of lower airway disease (9).
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A patient’s sensation of nasal patency may be a challenge for the 
clinician because it can be difficult to relate the subjective fee-
ling to anatomical and physiological variables, such as the inter-
nal nasal valve with minimal cross sectional area (10) and airflow. 
Further, nasal patency assessment with objective measures, 
such as Peak Nasal Inspiratory Flow (PNIF), has been evaluated 
in a large number of studies on healthy individuals (11-13), patients 
complaining of nasal obstruction (14), medical treatment of the 
nose (15), nasal surgery procedures (16,17) and repeatability (18). 
However, despite the well-known association between diseases 
in the upper and lower airways, very few have studied the use of 
PNIF on patients with pulmonary disorders (19,20). 
The aim of the present study was to investigate the effect of a di-
agnosis of asthma and of lung function on PNIF when adjusted 
for possible confounders. Further, we investigated the percep-
tion of nasal obstruction in asthmatics compared to healthy 
controls when adjusted for PNIF. 
Materials and methods
Study population
A cross-sectional study was conducted on 179 adult subjects 
consisting of 87 physician-diagnosed asthma patients and 92 
non asthmatic controls. The sample, nasal recordings, ques-
tionnaires, and additional recordings were extracted from a 
database described previously (21).
Asthma was defined as the presence of typical asthma 
symptoms, variable airflow obstruction and in accordance with 
the British Thoracic Society criteria (22). Variable airflow obstruc-
tion was defined by at least one of the two following criteria: an 
increase of ≥12% and ≥ 200 ml in the forced expiratory volume 
in the first second (FEV1) from baseline and after administration 
of salbutamol, or a positive bronchial provocation test, defined 
as the provocative dose of methacholine of ≤ 1600µg that cau-
ses a fall in FEV1 of at least 20% from baseline. Exclusion criteria 
were pregnancy, a history of cancer, previous nasal surgery, sys-
temic disease with potential affection of the nose such as granu-
lomatosis with polyangiitis (Wegener’s granulomatosis), cystic 
fibrosis, primary ciliary dyskinesia, Kartagener’s syndrome and 
sarcoidosis, and the presence of acute and chronic rhinosinusitis 
and nasal polyposis on oto-rhino-laryngological examination 
as defined by the EPOS2012 criteria (23). Control subjects with 
allergy were not investigated in the pollen season (May-August) 
and asthmatic subjects were investigated from September 2009 
to February 2010.
Written informed consent was obtained from all subjects. The 
study was approved by the Regional Committees for Medical 
and Health Research Ethics of Norway and investigations were 
performed in accordance with the principles of the Declaration 
of Helsinki.
Peak Nasal Inspiratory Flow (PNIF)
Nasal patency was assessed with a portable PNIF meter (In-
check DIAL, Clement Clarke International, Harlow, Essex, UK). 
A forced maximum inhalation through the nose from residual 
volume was performed with the subject sitting in an upright 
position. Three satisfactory maximal nasal inspirations were 
obtained, and the mean value was calculated. 
The scale on the PNIF meter was from 15 to 120 liters/minute (L/
min). A flow in excess of 120 L/min was recorded as 120+ L/min , 
and for the purpose of statistical analysis set to 120 L/min.
Spirometry
Lung function was assessed by flow-volume spirometry measu-
rements (Spirostar USB spirometer, Medikro Oy, Kuopio, Finland) 
at room temperature. The best FEV1 in liters and percentage of 
predicted (% predicted)(24) of three acceptable attempts was re-
corded, in accordance with international guidelines (25). Predicted 
normal values were based on reference values of Crapo et al. (24). 
 
Nasal minimal cross sectional area
The cross sectional areas from the nasal orifice to a depth of 5.2 
cm into the nasal cavity were assessed with acoustic rhinome-
try (RhinoMetrics SRE2100, Rhinoscan version 2.5, built 3.2.5.0; 
Interacoustics, Minneapolis, MN, USA) by two trained operators 
throughout the study. Recordings were performed according to 
published protocols (26). Three recordings were made from each 
nasal cavity. The mean value for each side was calculated from 
contiguous cross sectional areas from 0 to 3 cm and from 3 to 5.2 
cm. To account for variations between nostrils due to the nasal 
cycle, the average of the two mean values for each partition was 
calculated. The lower of the two averages was defined as the 
nasal minimal cross sectional area (MCA cm²).  
Allergy
Sensitization to pollen (birch, grass and mugwort), cladospo-
rium, house dust mite (Dermatophagoides pteronyssinus), and 
animal epithelia (horse, dog, and cat) was determined by skin 
prick testing (Soluprick SQ, ALK-Abello, Horsholm, Denmark) or 
measurement of specific IgE (AlaTOP, Diagnostics Products Corp., 
Los Angeles, CA, USA). Antihistamines were discontinued 4 days 
prior to the skin prick test. Allergy was defined as a positive test 
(reaction with a ≥3-mm-diameter wheal or specific IgE concen-
tration of 0.7 IU/ml or greater) and typical symptoms of hyper-
sensitivity on exposure to the allergen(s).
Nasal obstruction
The subjective degree of nasal obstruction during the previous 
week was assessed on a 100 mm Visual Analog Scale (NO-VAS) 
and the endpoints were 0 mm (never) and 100 mm (always).
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Variable Total, n = 179 Asthma, n = 87 Control, n = 92 p
Age, years median, (range) 44 (19-65) 44 (19-64) 44 (20-65) 0.91
BMI, kg/m² median, (range) 25.4 (18.0-44.3) 25.7 (18.5-44.3) 25.0 (18.0-35.4) 0.08
Sex, Male/female 76/103 36/51 40/52 0.78
Allergy n (%) 72 (40) 52 (60) 20 (22) <0.01
Smoking status: Ever/Never 32/147 11/76 21/71 0.08
Level of education in year <0.01
≤ 9 years n (%) 36 (20) 15 (42) 21 (58)
10 to 12 years n (%) 75 (42) 47 (63) 28 (37)
≥ 13 years n (%) 68 (38) 25 (37) 43 (63)
Table 1. Demographic data on asthmatics and controls.
BMI = body mass index
Statistical analysis
Data were described with median and range for continuous va-
riables and with count and percentages for categorical variables. 
Crude associations between pairs of categorical variables were 
assessed with Chi-square tests.
The level of education was categorized as either basic (≤ 9 
years), secondary (10 to 12 years), or tertiary (≥ 13 years), that 
has been shown to be a good surrogate for socioeconomic 
status in Norway (27,28). Subject co-morbidity was defined as the 
regular use of medication during the last 6 months prior to 
recruitment for asthma and allergy, pain relief, ischemic heart 
disease and hypertension, musculoskeletal disease, thyroid dis-
orders, diabetes mellitus, anxiety and depression. Disease status 
was categorized as cardiovascular disease, other disease and no 
disease. Smoking status was dichotomized as smoker (current 
or ever smoked) and nonsmoker, as we did not have precise 
information about cigarette consumption. 
NO-VAS was categorized as mild (0-30 mm), moderate (31-70 
mm) and severe (71-100 mm)(29). PNIF was used as a continuous 
variable for linear regression analysis and as an ordinal variable 
for ordinal logistic regression analysis. For the latter analysis, 
PNIF was categorized into the following 3 groups: (1) high: ≥ 120 
L/min, (2) medium: 90 - 119 L/min and (3) low: 15 - 89 L/min. 
Of the spirometry variables, FEV1 is the most robust, and FEV1 
(% predicted) was chosen for linear regression as that is based 
on height, age, sex and ethnicity of the subject. As there was 
a strong association between asthma and FEV1 (% predicted) 
(t-test, p < 0.001), we fitted two separate models for PNIF as a 
continuous variable to avoid multicollinearity. The associations 
between PNIF and asthma and between PNIF and FEV1 (% pre-
dicted) were modeled with linear regression. Possible confoun-
ders such as allergy, other diseases, education, NO-VAS, MCA, 
weight, height, age, sex and smoking were tested. The model fit 
was good and assumption of normally distributed residuals was 
fulfilled. 
Further, we fitted ordinal logistic regression to assess possi-
ble association between VAS (in three categories) and having 
asthma. PNIF was omitted from the final model as we found 
the same ratio between having asthma and VAS score when 
stratified by PNIF group so there was no interaction between 
PNIF and asthma. The assumption of parallel lines was fulfilled 
and the model fit was good. The results were expressed as odds 
ratios (OR) with 95% confidence intervals (CI). 
All statistical analyses were performed using PASW Statistics, 
version 20 for Windows (SPSS Inc., Chicago, IL, USA).  A p-value 
of < 0.01 was considered statistically significant to correct for 
multiple testing.
Results 
Subject characteristics are presented in Table 1. Allergy was pre-
sent in 60 % (n = 52) of asthmatics and 22 % (n = 20) of controls. 
The association between asthma and PNIF is shown in Model 1 
(Table 2A). PNIF was significantly associated with asthma, MCA 
and age (p < 0.01). When all other confounders were kept equal, 
PNIF was 10 L/min lower in asthmatics than non-asthmatics. 
Further, PNIF was increased by 4.9 L/min for a 0.1 cm2 increase 
in MCA, and was decreased by 0.4 L/min per one year increase 
in age.
The association between FEV1 (% predicted) and PNIF is shown 
in Model 2 (Table 2B). PNIF was significantly associated with 
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Allergy and smoking status were not significantly associated 
with PNIF in any of the adjusted analyses. 
Asthma patients were 19 times more likely to be in a higher VAS 
category compared to non-asthmatic controls (OR = 19.4, 95 % 
CI 7.2-52.5, p < 0.001). The odds ratio was independent of the 
PNIF group (Figure 1).
FEV1 (% predicted), MCA, NO-VAS and other disease (p < 0.01). 
When all other confounders were kept equal, PNIF increased by 
0.3 L/min per % increase in FEV1 (% predicted), and increased 
by 5.1 L/min for every 0.1 cm2 increase in MCA. There was a 
decrease of 0.2 L/min in PNIF per mm increase in NO-VAS and 
a decrease of 6.1 L/min in PNIF in subjects categorized with a 
disease. 
Variable Estimate of β 95% CI p-value
Asthma [no=ref ] -10.2 -17.8 to -2.7 <0.01
Allergy [no=ref ] -0.1 -6.6 to 6.4 0.98
Disease status [no=ref ] -4.7 -8.6 to -0.7 0.02
Education level [basic=ref ] 2.5 -2.1 to 7.0 0.29
NO-VAS [mm] -0.2 -0.3 to -0.01 0.03
MCA [0.1 cm2] 4.9 2.2 to 7.6 <0.01
Weight [kg] 0.2 0.0 to 0.5 0.05
Height [cm] -0.1 -0.6 to 0.4 0.8
Age [years] -0.4 -0.6 to -0.1 <0.01
Sex [male=ref ] -3.1 -12.6 to 6.4 0.5
Smoking [ever=ref ] 0.5 -7.2 to 8.3 0.9
Table 2. Multiple linear regression for PNIF as a dependent variable.
A) Model 1: Asthma as an independent variable adjusted for confounders. N=179
Variable Estimate of β 95% CI p-value
FEV1 (% predicted) [%] 0.3  0.1 to 0.5 <0.01
Allergy [no=ref ] -0.3 -6.4 to 5.9 0.9
Disease status [no=ref ] -6.1 -9.9 to -2.4 <0.01
Education [basic=ref ] 4.5 0.4 to 8.6 0.03
NO-VAS [mm] -0.2 -0.3 to -0.07 <0.01
MCA [0.1 cm2] 5.1 2.5 to 7.6 <0.01
Weight [kg] 0.2 0.1 to 0.4 0.01
Smoking [ever=ref ] 2.7 -4.9 to 10.5 0.5
B) Model 2: FEV1 (% predicted) as an independent variable adjusted for confounders. N=179
Estimate of beta = the amount of change in the response variable when the explanatory variable is increased by one unit. FEV1 = forced expiratory 
volume in the first second, MCA = minimal cross sectional area, NO-VAS = nasal obstruction visual analogue scale, PNIF = peak nasal inspiratory flow, 
ref = reference category for categorical variables.
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Discussion
This study demonstrates that PNIF is influenced by an asthma 
diagnosis and FEV1 (% predicted), and that asthmatics are more 
likely to be in a higher NO-VAS category which is independent 
of PNIF group. Other factors associated with PNIF are the degree 
of nasal obstruction measured both subjectively on a visual ana-
logue scale and objectively with acoustic rhinometry, age and 
disease status. Thus in patients presenting with nasal obstruc-
tion PNIF recordings should be assessed in conjunction with an 
asthma diagnosis, spirometry and MCA.
In the present study, PNIF is 10 L/min lower in asthmatics than in 
non-asthmatics and increases by 0.3 L/min for every % increase 
in FEV1 (% predicted). Thus, when confronted with a patient 
with nasal obstruction without an obvious rhinological cause, 
the possibility of asthma should be considered. The clinician 
should enquire about lower respiratory tract symptoms sugges-
tive of asthma and seek evidence of variable airflow obstruction 
either with spirometry and reversibility testing or assessing the 
degree of bronchial hyperresponsiveness. Previous studies show 
a positive correlation between upper airway patency measured 
by PNIF and lower airway function measured by PEF in adults 
(12) and in children and adolescents (30). Moreover, an increase 
in PNIF with a concomitant increase in FEV1 (% predicted) has 
been reported in allergic rhinitis after sauna treatment (31). 
PNIF increased by 4.9-5.1 L/min per 0.1 cm² increase in MCA 
when modeled with respect to an asthma diagnosis (Model 1) 
or by FEV1 (% predicted) as in model 2. The MCA in our sample 
was located between 0-3 cm from the nasal orifice in almost 
all of our subjects (95% of asthmatics and 98% of controls) (21). 
The internal nasal valve is generally accepted to be located at a 
distance of 2-3 cm from the nasal orifice (10,32), and surgical proce-
dures performed at the internal nasal valve improve MCA (33-35). 
Improvement in MCA should lead to a significant improvement 
in nasal airflow as Poiseuille’s law states that flow is directly 
proportional to the difference in pressure times the radius raised 
to the fourth power (36), even though modifications due to the 
complex flow patterns in the human nose must be taken into 
consideration (37). Thus, in asthmatics with obstructed noses, sur-
gical intervention with procedures aimed at the internal nasal 
valve, could lead to an improvement in nasal air flow which in 
turn might be beneficial for the lower airways.
We have also shown that asthmatics have a different sensation 
of nasal obstruction compared to non-asthmatics despite being 
in the same PNIF group. The likelihood of being in a higher NO-
VAS category is 19–fold greater in asthmatics than in non-asth-
matic subjects. However, the inter-individual variation is large, as 
confirmed by the wide confidence interval and it is thus difficult 
to quantify this association with better precision. Despite this, 
one can speculate whether an increased number of sensory 
sodium channels and sensory- and secretomotor nerve fibers in 
the nasal mucosa, that has been reported in allergic and non-
allergic rhinitis (38,39), may account for the increased perception 
of nasal obstruction. The level of perceived breathing difficulty 
has been reported to be more important than the applied nasal 
load for the increased propensity of asthmatics to switch to 
oronasal breathing, compared with non-asthmatic subjects (40).  
Premature switching to oronasal breathing results in inadequate 
conditioning and filtering of the inspired air, with drying and 
cooling of the lower airways, subsequent release of inflamma-
tory cell mediators and development of an asthmatic response 
(41) and asthma chronicity. 
The main strengths of our study are the large sample size, pos-
sibility to compare asthmatics with non-asthmatics, and the 
complete information of many possible confounders. Howe-
ver, the study has some limitations. Smoking is known to be 
under-reported, and we only have information about ever- and 
never smokers. The information about other diseases was self-
reported and might be underestimated. The non-asthmatics 
were individuals recruited from businesses near by the hospital 
or patients attending the hospital for other illnesses, which were 
thought not to affect the upper and lower airways. Those who 
chose to participate may have been more interested in their 
health than the general population, but still we regard measure-
ments on these individuals to be representative for the general 
population. 
Figure 1. NO-VAS distribution according to PNIF group in asthmatics and 
controls. NO-VAS= nasal obstruction visual analogue scale, PNIF= peak 
nasal inspiratory flow.
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There are different PNIF meters in clinical use, and our study 
is based on In-check DIAL which has a scale from 15 to 120 L/
min. A normal value of greater than 120 L/min is commonly 
used (42). Regarding the individuals with PNIF > 120 L/min (5 
asthmatics and 21 controls), we have performed sensitivity 
analysis where these individuals were omitted which confirms 
our original findings.
Mainly turbulent airflow prevails at tidal volumes reached 
during maximum inspiration (43) and thus PNIF does not 
reflect the nasal resistance during resting respiration. Possible 
reasons for inaccuracy of the PNIF include random error and 
operation errors such as measurement with loose face masks 
or incompletely closed mouth, but these errors were minimali-
zed by two trained operators throughout the study.
The present study emphasizes that special care has to be 
taken when interpreting PNIF values in patients with asthma 
or reduced FEV1 (% predicted). The sensation of nasal obstruc-
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